[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fb2iJ6b9fgFiuVjaKeweGDTpqrJTpcATXYI574UHJY9s":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":38,"phaseBuckets":54,"rows":61},"Centers for Disease Control and Prevention",[4,6],"Centers for Disease Control and Prevention, China",295,false,5,46,2245874,14,163,[15,18,21,24,26,29,32,35],{"name":16,"count":17},"HIV Infections",39,{"name":19,"count":20},"Malaria",23,{"name":22,"count":23},"HIV",20,{"name":25,"count":23},"Tuberculosis",{"name":27,"count":28},"Poliomyelitis",15,{"name":30,"count":31},"Influenza",12,{"name":33,"count":34},"Sexually Transmitted Diseases",11,{"name":36,"count":37},"Diarrhea",8,[39,44,49],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06962904","CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults","2026-10-06","3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05766267","Short-course Regimens for the Treatment of Pulmonary Tuberculosis","2026-12-31","Rifabutin",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT03474029","Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI","2029-12-31","Rifapentine daily for 6 weeks",[55,56,57,58,59,60],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[62,136,154,172,197,215,233,251,331,386,435,462,488,519,541,578,600,634,670,708,744,771,789,815,833,851,879,897,915,933,958,983,1011,1029,1047,1065,1083,1114,1132,1150,1168,1186,1204,1222,1240,1263,1289,1307,1332,1361,1387,1405,1431,1449,1467,1485,1511,1529,1547,1565,1583,1601,1627,1645,1663,1687,1710,1728,1759,1788,1806,1824,1842,1860,1878,1904,1931,1949,1975,1993,2019,2037,2062,2080,2105,2132,2150,2168,2186,2204,2229,2247,2273,2291,2319,2337,2355,2379,2403,2428,2454,2472,2499,2522,2546,2571,2589,2613,2636,2661,2679,2705,2723,2750,2768,2792,2817,2842,2865,2890,2908,2935,2953,2977,3000,3018,3036,3061,3079,3097,3115,3139,3167,3191,3216,3234,3252,3278,3296,3314,3335,3357,3381,3399,3425,3470,3538,3581,3615,3646,3679,3715,3750,3780,3811,3833,3863,3897,3929,3956,3974,3997,4023,4045,4068,4090,4108,4133,4151,4169,4187,4205,4223,4248,4271,4295,4313,4340,4362,4388,4406,4424,4442,4471,4489,4510,4528,4552,4570,4597,4615,4639,4664,4682],{"intervention":63,"totalTrials":9,"cells":64},"Moxifloxacin",{"EARLY_PHASE1":65,"PHASE1":68,"PHASE2":70,"PHASE3":105,"PHASE4":132,"NA":134},{"trials":66,"activeCount":67},[],0,{"trials":69,"activeCount":67},[],{"trials":71,"activeCount":67},[72,84,94],{"nctId":73,"briefTitle":74,"status":75,"phases":76,"primaryCompletion":77,"completion":78,"start":79,"enrollment":80,"conditions":81,"interventions":82},"NCT00144417","TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment","COMPLETED",[57],"2007-06","2007-12","2006-02",433,[25],[63,83],"isoniazid",{"nctId":85,"briefTitle":86,"status":75,"phases":87,"primaryCompletion":88,"completion":88,"start":89,"enrollment":90,"conditions":91,"interventions":92},"NCT00164463","TBTC Study 27\u002F28 PK: Moxifloxacin Pharmacokinetics During TB Treatment",[57],"2007-08","2004-07",72,[25],[63,93],"Isoniazid",{"nctId":95,"briefTitle":96,"status":75,"phases":97,"completion":98,"start":99,"enrollment":100,"conditions":101,"interventions":103},"NCT00140309","TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment",[57],"2005-12","2003-07",350,[102],"Tuberculosis, Pulmonary",[104],"moxifloxacin",{"trials":106,"activeCount":131,"soonestReadout":47},[107,120],{"nctId":108,"briefTitle":109,"status":75,"phases":110,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":115},"NCT02563327","Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis",[58],"2021-08-30","2016-05-30",53,[25],[116,63,117,93,118,119],"Rifapentine","Rifampin","Pyrazinamide","Ethambutol",{"nctId":45,"briefTitle":46,"status":121,"phases":122,"primaryCompletion":47,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":128},"ACTIVE_NOT_RECRUITING",[57,58],"2027-12-31","2023-11-21",288,[102,127],"Tuberculosis Infection",[48,129,130,63,118,93,117,119],"Delamanid","Bedaquiline",1,{"trials":133,"activeCount":67},[],{"trials":135,"activeCount":67},[],{"intervention":129,"totalTrials":131,"cells":137},{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":150,"NA":152},{"trials":139,"activeCount":67},[],{"trials":141,"activeCount":67},[],{"trials":143,"activeCount":67},[],{"trials":145,"activeCount":131,"soonestReadout":47},[146],{"nctId":45,"briefTitle":46,"status":121,"phases":147,"primaryCompletion":47,"completion":123,"start":124,"enrollment":125,"conditions":148,"interventions":149},[57,58],[102,127],[48,129,130,63,118,93,117,119],{"trials":151,"activeCount":67},[],{"trials":153,"activeCount":67},[],{"intervention":130,"totalTrials":131,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":168,"NA":170},{"trials":157,"activeCount":67},[],{"trials":159,"activeCount":67},[],{"trials":161,"activeCount":67},[],{"trials":163,"activeCount":131,"soonestReadout":47},[164],{"nctId":45,"briefTitle":46,"status":121,"phases":165,"primaryCompletion":47,"completion":123,"start":124,"enrollment":125,"conditions":166,"interventions":167},[57,58],[102,127],[48,129,130,63,118,93,117,119],{"trials":169,"activeCount":67},[],{"trials":171,"activeCount":67},[],{"intervention":53,"totalTrials":131,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":193,"NA":195},{"trials":175,"activeCount":67},[],{"trials":177,"activeCount":67},[],{"trials":179,"activeCount":67},[],{"trials":181,"activeCount":131,"soonestReadout":52},[182],{"nctId":50,"briefTitle":51,"status":183,"phases":184,"primaryCompletion":52,"completion":52,"start":185,"enrollment":186,"conditions":187,"interventions":189},"RECRUITING",[57,58],"2019-08-01",3400,[188],"Latent Tuberculosis",[53,190,191,192],"Rifapentine and Isoniazid weekly for 12 weeks","Rifampin and Isoniazid daily for 12 weeks","Rifampin daily for 16 weeks",{"trials":194,"activeCount":67},[],{"trials":196,"activeCount":67},[],{"intervention":190,"totalTrials":131,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":205,"PHASE4":211,"NA":213},{"trials":200,"activeCount":67},[],{"trials":202,"activeCount":67},[],{"trials":204,"activeCount":67},[],{"trials":206,"activeCount":131,"soonestReadout":52},[207],{"nctId":50,"briefTitle":51,"status":183,"phases":208,"primaryCompletion":52,"completion":52,"start":185,"enrollment":186,"conditions":209,"interventions":210},[57,58],[188],[53,190,191,192],{"trials":212,"activeCount":67},[],{"trials":214,"activeCount":67},[],{"intervention":191,"totalTrials":131,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":229,"NA":231},{"trials":218,"activeCount":67},[],{"trials":220,"activeCount":67},[],{"trials":222,"activeCount":67},[],{"trials":224,"activeCount":131,"soonestReadout":52},[225],{"nctId":50,"briefTitle":51,"status":183,"phases":226,"primaryCompletion":52,"completion":52,"start":185,"enrollment":186,"conditions":227,"interventions":228},[57,58],[188],[53,190,191,192],{"trials":230,"activeCount":67},[],{"trials":232,"activeCount":67},[],{"intervention":192,"totalTrials":131,"cells":234},{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":241,"PHASE4":247,"NA":249},{"trials":236,"activeCount":67},[],{"trials":238,"activeCount":67},[],{"trials":240,"activeCount":67},[],{"trials":242,"activeCount":131,"soonestReadout":52},[243],{"nctId":50,"briefTitle":51,"status":183,"phases":244,"primaryCompletion":52,"completion":52,"start":185,"enrollment":186,"conditions":245,"interventions":246},[57,58],[188],[53,190,191,192],{"trials":248,"activeCount":67},[],{"trials":250,"activeCount":67},[],{"intervention":93,"totalTrials":252,"cells":253},9,{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":278,"PHASE4":307,"NA":319},{"trials":255,"activeCount":67},[],{"trials":257,"activeCount":67},[],{"trials":259,"activeCount":67},[260,264,268],{"nctId":73,"briefTitle":74,"status":75,"phases":261,"primaryCompletion":77,"completion":78,"start":79,"enrollment":80,"conditions":262,"interventions":263},[57],[25],[63,83],{"nctId":85,"briefTitle":86,"status":75,"phases":265,"primaryCompletion":88,"completion":88,"start":89,"enrollment":90,"conditions":266,"interventions":267},[57],[25],[63,93],{"nctId":269,"briefTitle":270,"status":75,"phases":271,"primaryCompletion":272,"completion":273,"start":274,"enrollment":275,"conditions":276,"interventions":277},"NCT03730181","Tuberculosis Clinical Trials Consortium Study 35",[56,57],"2024-12-15","2025-05-15","2019-10-12",62,[188],[116,93],{"trials":279,"activeCount":131,"soonestReadout":47},[280,284,294,298],{"nctId":108,"briefTitle":109,"status":75,"phases":281,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":282,"interventions":283},[58],[25],[116,63,117,93,118,119],{"nctId":285,"briefTitle":286,"status":75,"phases":287,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":293},"NCT00023335","TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis",[58],"2001-03","1995-04",1000,[292],"Pulmonary Tuberculosis",[116,93],{"nctId":45,"briefTitle":46,"status":121,"phases":295,"primaryCompletion":47,"completion":123,"start":124,"enrollment":125,"conditions":296,"interventions":297},[57,58],[102,127],[48,129,130,63,118,93,117,119],{"nctId":299,"briefTitle":300,"status":75,"phases":301,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":306},"NCT00023348","TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB",[57,58],"2002-11","1999-07",150,[16,25],[93,48],{"trials":308,"activeCount":67},[309],{"nctId":310,"briefTitle":311,"status":75,"phases":312,"primaryCompletion":313,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":318},"NCT00164281","Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana",[59],"2009-07","2011-05","2004-11",1995,[25,16],[93],{"trials":320,"activeCount":67},[321],{"nctId":322,"briefTitle":323,"status":75,"phases":324,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":329},"NCT00023387","TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine",[60],"2001-05","2000-03",36,[25],[116,330,93],"25-desacetyl Rifapentine",{"intervention":117,"totalTrials":9,"cells":332},{"EARLY_PHASE1":333,"PHASE1":335,"PHASE2":337,"PHASE3":361,"PHASE4":371,"NA":373},{"trials":334,"activeCount":67},[],{"trials":336,"activeCount":67},[],{"trials":338,"activeCount":67},[339,351],{"nctId":340,"briefTitle":341,"status":75,"phases":342,"primaryCompletion":343,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":348},"NCT00694629","TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment",[57],"2013-06","2013-12","2008-12",865,[292],[349,350,350,350],"rifampin","rifapentine",{"nctId":352,"briefTitle":353,"status":75,"phases":354,"completion":355,"start":99,"enrollment":356,"conditions":357,"interventions":359},"NCT00127504","Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness",[57],"2004-05",80,[358],"Onchocerciasis",[117,360],"Azithromycin",{"trials":362,"activeCount":131,"soonestReadout":47},[363,367],{"nctId":108,"briefTitle":109,"status":75,"phases":364,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":365,"interventions":366},[58],[25],[116,63,117,93,118,119],{"nctId":45,"briefTitle":46,"status":121,"phases":368,"primaryCompletion":47,"completion":123,"start":124,"enrollment":125,"conditions":369,"interventions":370},[57,58],[102,127],[48,129,130,63,118,93,117,119],{"trials":372,"activeCount":67},[],{"trials":374,"activeCount":67},[375],{"nctId":376,"briefTitle":377,"status":75,"phases":378,"primaryCompletion":379,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":384},"NCT00023374","TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance",[60],"2006-12","2010-12","2000-08",98,[25],[117,118,119,385],"REZ",{"intervention":48,"totalTrials":9,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":403,"PHASE4":413,"NA":424},{"trials":389,"activeCount":67},[],{"trials":391,"activeCount":67},[],{"trials":393,"activeCount":67},[394],{"nctId":395,"briefTitle":396,"status":75,"phases":397,"primaryCompletion":398,"completion":398,"start":399,"enrollment":23,"conditions":400,"interventions":401},"NCT00023413","TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz",[57],"2004-02","1999-11",[16,25],[48,402],"Efavirenz",{"trials":404,"activeCount":131,"soonestReadout":47},[405,409],{"nctId":45,"briefTitle":46,"status":121,"phases":406,"primaryCompletion":47,"completion":123,"start":124,"enrollment":125,"conditions":407,"interventions":408},[57,58],[102,127],[48,129,130,63,118,93,117,119],{"nctId":299,"briefTitle":300,"status":75,"phases":410,"completion":302,"start":303,"enrollment":304,"conditions":411,"interventions":412},[57,58],[16,25],[93,48],{"trials":414,"activeCount":67},[415],{"nctId":416,"briefTitle":417,"status":75,"phases":418,"completion":419,"start":420,"enrollment":23,"conditions":421,"interventions":422},"NCT00023400","TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB",[59],"2002-02","2000-02",[16,25],[423,48],"Nelfinavir",{"trials":425,"activeCount":67},[426],{"nctId":427,"briefTitle":428,"status":75,"phases":429,"completion":430,"start":431,"enrollment":432,"conditions":433,"interventions":434},"NCT00023361","TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen",[60],"2003-02","1999-02",215,[16,25],[48],{"intervention":118,"totalTrials":436,"cells":437},3,{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":444,"PHASE4":454,"NA":456},{"trials":439,"activeCount":67},[],{"trials":441,"activeCount":67},[],{"trials":443,"activeCount":67},[],{"trials":445,"activeCount":131,"soonestReadout":47},[446,450],{"nctId":108,"briefTitle":109,"status":75,"phases":447,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":448,"interventions":449},[58],[25],[116,63,117,93,118,119],{"nctId":45,"briefTitle":46,"status":121,"phases":451,"primaryCompletion":47,"completion":123,"start":124,"enrollment":125,"conditions":452,"interventions":453},[57,58],[102,127],[48,129,130,63,118,93,117,119],{"trials":455,"activeCount":67},[],{"trials":457,"activeCount":67},[458],{"nctId":376,"briefTitle":377,"status":75,"phases":459,"primaryCompletion":379,"completion":380,"start":381,"enrollment":382,"conditions":460,"interventions":461},[60],[25],[117,118,119,385],{"intervention":119,"totalTrials":436,"cells":463},{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":470,"PHASE4":480,"NA":482},{"trials":465,"activeCount":67},[],{"trials":467,"activeCount":67},[],{"trials":469,"activeCount":67},[],{"trials":471,"activeCount":131,"soonestReadout":47},[472,476],{"nctId":108,"briefTitle":109,"status":75,"phases":473,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":474,"interventions":475},[58],[25],[116,63,117,93,118,119],{"nctId":45,"briefTitle":46,"status":121,"phases":477,"primaryCompletion":47,"completion":123,"start":124,"enrollment":125,"conditions":478,"interventions":479},[57,58],[102,127],[48,129,130,63,118,93,117,119],{"trials":481,"activeCount":67},[],{"trials":483,"activeCount":67},[484],{"nctId":376,"briefTitle":377,"status":75,"phases":485,"primaryCompletion":379,"completion":380,"start":381,"enrollment":382,"conditions":486,"interventions":487},[60],[25],[117,118,119,385],{"intervention":43,"totalTrials":489,"cells":490},2,{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":511,"PHASE3":513,"PHASE4":515,"NA":517},{"trials":492,"activeCount":67},[],{"trials":494,"activeCount":131,"soonestReadout":42},[495,503],{"nctId":40,"briefTitle":41,"status":121,"phases":496,"primaryCompletion":42,"completion":42,"start":497,"enrollment":498,"conditions":499,"interventions":501},[56],"2025-07-07",50,[500],"Rotavirus Infections",[43,502],"7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine",{"nctId":504,"briefTitle":505,"status":75,"phases":506,"primaryCompletion":507,"completion":507,"start":508,"enrollment":498,"conditions":509,"interventions":510},"NCT06485258","CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults",[56],"2026-02-04","2024-08-06",[500],[43,502],{"trials":512,"activeCount":67},[],{"trials":514,"activeCount":67},[],{"trials":516,"activeCount":67},[],{"trials":518,"activeCount":67},[],{"intervention":502,"totalTrials":489,"cells":520},{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":533,"PHASE3":535,"PHASE4":537,"NA":539},{"trials":522,"activeCount":67},[],{"trials":524,"activeCount":131,"soonestReadout":42},[525,529],{"nctId":40,"briefTitle":41,"status":121,"phases":526,"primaryCompletion":42,"completion":42,"start":497,"enrollment":498,"conditions":527,"interventions":528},[56],[500],[43,502],{"nctId":504,"briefTitle":505,"status":75,"phases":530,"primaryCompletion":507,"completion":507,"start":508,"enrollment":498,"conditions":531,"interventions":532},[56],[500],[43,502],{"trials":534,"activeCount":67},[],{"trials":536,"activeCount":67},[],{"trials":538,"activeCount":67},[],{"trials":540,"activeCount":67},[],{"intervention":542,"totalTrials":489,"cells":543},"Amodiaquine plus artesunate",{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":550,"PHASE4":552,"NA":576},{"trials":545,"activeCount":67},[],{"trials":547,"activeCount":67},[],{"trials":549,"activeCount":67},[],{"trials":551,"activeCount":67},[],{"trials":553,"activeCount":67},[554,565],{"nctId":555,"briefTitle":556,"status":75,"phases":557,"primaryCompletion":558,"completion":558,"start":559,"enrollment":560,"conditions":561,"interventions":563},"NCT00164359","Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi",[59],"2005-09","2005-04",212,[562],"Malaria, Falciparum",[542,564],"chlorproguanil-dapsone plus artesunate",{"nctId":566,"briefTitle":567,"status":75,"phases":568,"primaryCompletion":558,"completion":558,"start":559,"enrollment":569,"conditions":570,"interventions":571},"NCT00164710","Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi",[59],365,[562],[572,573,574,564,575],"sulfadoxine-pyrimethamine","amodiaquine plus sulfadoxine-pyrimethamine","amodiaquine plus artesunate","lumefantrine-artemether",{"trials":577,"activeCount":67},[],{"intervention":564,"totalTrials":489,"cells":579},{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":586,"PHASE4":588,"NA":598},{"trials":581,"activeCount":67},[],{"trials":583,"activeCount":67},[],{"trials":585,"activeCount":67},[],{"trials":587,"activeCount":67},[],{"trials":589,"activeCount":67},[590,594],{"nctId":555,"briefTitle":556,"status":75,"phases":591,"primaryCompletion":558,"completion":558,"start":559,"enrollment":560,"conditions":592,"interventions":593},[59],[562],[542,564],{"nctId":566,"briefTitle":567,"status":75,"phases":595,"primaryCompletion":558,"completion":558,"start":559,"enrollment":569,"conditions":596,"interventions":597},[59],[562],[572,573,574,564,575],{"trials":599,"activeCount":67},[],{"intervention":601,"totalTrials":489,"cells":602},"Sabin IPV",{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":607,"PHASE3":609,"PHASE4":611,"NA":632},{"trials":604,"activeCount":67},[],{"trials":606,"activeCount":67},[],{"trials":608,"activeCount":67},[],{"trials":610,"activeCount":67},[],{"trials":612,"activeCount":67},[613,623],{"nctId":614,"briefTitle":615,"status":75,"phases":616,"primaryCompletion":617,"completion":618,"start":619,"enrollment":620,"conditions":621,"interventions":622},"NCT03597919","A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China.",[59],"2019-09-30","2020-01-15","2018-05-28",560,[27],[601],{"nctId":624,"briefTitle":625,"status":75,"phases":626,"primaryCompletion":627,"completion":618,"start":628,"enrollment":629,"conditions":630,"interventions":631},"NCT03546634","Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China",[59],"2019-06-05","2018-05-24",280,[27],[601],{"trials":633,"activeCount":67},[],{"intervention":635,"totalTrials":489,"cells":636},"bOPV",{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":643,"PHASE4":645,"NA":668},{"trials":638,"activeCount":67},[],{"trials":640,"activeCount":67},[],{"trials":642,"activeCount":67},[],{"trials":644,"activeCount":67},[],{"trials":646,"activeCount":67},[647,657],{"nctId":648,"briefTitle":649,"status":75,"phases":650,"primaryCompletion":651,"completion":651,"start":652,"enrollment":653,"conditions":654,"interventions":655},"NCT02412514","Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules",[59],"2015-12","2015-04",456,[27],[635,635,656],"IPV",{"nctId":658,"briefTitle":659,"status":75,"phases":660,"primaryCompletion":661,"completion":661,"start":662,"enrollment":663,"conditions":664,"interventions":665},"NCT03722004","Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study",[59],"2019-12-19","2018-12-18",1256,[27],[666,635,667],"mOPV1","fIPV",{"trials":669,"activeCount":67},[],{"intervention":671,"totalTrials":489,"cells":672},"Acyclovir",{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":677,"PHASE3":679,"PHASE4":693,"NA":706},{"trials":674,"activeCount":67},[],{"trials":676,"activeCount":67},[],{"trials":678,"activeCount":67},[],{"trials":680,"activeCount":67},[681],{"nctId":682,"briefTitle":683,"status":75,"phases":684,"primaryCompletion":685,"completion":686,"start":687,"enrollment":688,"conditions":689,"interventions":692},"NCT00164424","Episodic Acyclovir Therapy for Genital Ulcers",[57,58],"2009-03","2011-07","2005-03",613,[16,690,691],"Ulcer","Herpes Simplex",[671],{"trials":694,"activeCount":67},[695],{"nctId":696,"briefTitle":697,"status":75,"phases":698,"completion":699,"start":700,"enrollment":701,"conditions":702,"interventions":704},"NCT00362596","A Randomized Controlled Trial of Acyclovir Among HIV and HSV-2 Co-Infected Women, Chiang Rai, Thailand",[59],"2005-08","2005-01",67,[22,703],"Herpes",[705],"acyclovir",{"trials":707,"activeCount":67},[],{"intervention":709,"totalTrials":489,"cells":710},"Mefloquine- Artesunate",{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":717,"PHASE4":719,"NA":742},{"trials":712,"activeCount":67},[],{"trials":714,"activeCount":67},[],{"trials":716,"activeCount":67},[],{"trials":718,"activeCount":67},[],{"trials":720,"activeCount":67},[721,734],{"nctId":722,"briefTitle":723,"status":724,"phases":725,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":729,"interventions":731},"NCT01107145","Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)","TERMINATED",[59],"2012-01","2011-02",16,[730],"Plasmodium Vivax Malaria",[709,732,733],"Artemether-Lumefantrine","Chloroquine",{"nctId":735,"briefTitle":736,"status":724,"phases":737,"primaryCompletion":726,"completion":726,"start":738,"enrollment":739,"conditions":740,"interventions":741},"NCT01082731","Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil",[59],"2010-11",6,[19],[732,709],{"trials":743,"activeCount":67},[],{"intervention":745,"totalTrials":131,"cells":746},"Amodiaquine-artesunate",{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":753,"PHASE4":755,"NA":769},{"trials":748,"activeCount":67},[],{"trials":750,"activeCount":67},[],{"trials":752,"activeCount":67},[],{"trials":754,"activeCount":67},[],{"trials":756,"activeCount":67},[757],{"nctId":758,"briefTitle":759,"status":75,"phases":760,"primaryCompletion":761,"completion":761,"start":762,"enrollment":763,"conditions":764,"interventions":767},"NCT06300970","Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia",[59],"2023-08-16","2022-08-09",352,[765,19,766],"Plasmodium Falciparum","Uncomplicated Malaria",[745,768],"Artemether+Lumefantrine",{"trials":770,"activeCount":67},[],{"intervention":768,"totalTrials":131,"cells":772},{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":779,"PHASE4":781,"NA":787},{"trials":774,"activeCount":67},[],{"trials":776,"activeCount":67},[],{"trials":778,"activeCount":67},[],{"trials":780,"activeCount":67},[],{"trials":782,"activeCount":67},[783],{"nctId":758,"briefTitle":759,"status":75,"phases":784,"primaryCompletion":761,"completion":761,"start":762,"enrollment":763,"conditions":785,"interventions":786},[59],[765,19,766],[745,768],{"trials":788,"activeCount":67},[],{"intervention":790,"totalTrials":131,"cells":791},"fIPV (0.1 mL) ID",{"EARLY_PHASE1":792,"PHASE1":794,"PHASE2":796,"PHASE3":798,"PHASE4":800,"NA":813},{"trials":793,"activeCount":67},[],{"trials":795,"activeCount":67},[],{"trials":797,"activeCount":67},[],{"trials":799,"activeCount":67},[],{"trials":801,"activeCount":67},[802],{"nctId":803,"briefTitle":804,"status":724,"phases":805,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":809,"interventions":810},"NCT04063150","Immunogenicity of Intramuscular and Intradermal IPV",[59],"2020-03-25","2019-10-06",958,[27],[790,811,812,656],"fIPV (0.1mL) IM","fIPV (0.2mL) IM",{"trials":814,"activeCount":67},[],{"intervention":811,"totalTrials":131,"cells":816},{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":823,"PHASE4":825,"NA":831},{"trials":818,"activeCount":67},[],{"trials":820,"activeCount":67},[],{"trials":822,"activeCount":67},[],{"trials":824,"activeCount":67},[],{"trials":826,"activeCount":67},[827],{"nctId":803,"briefTitle":804,"status":724,"phases":828,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":829,"interventions":830},[59],[27],[790,811,812,656],{"trials":832,"activeCount":67},[],{"intervention":812,"totalTrials":131,"cells":834},{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":841,"PHASE4":843,"NA":849},{"trials":836,"activeCount":67},[],{"trials":838,"activeCount":67},[],{"trials":840,"activeCount":67},[],{"trials":842,"activeCount":67},[],{"trials":844,"activeCount":67},[845],{"nctId":803,"briefTitle":804,"status":724,"phases":846,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":847,"interventions":848},[59],[27],[790,811,812,656],{"trials":850,"activeCount":67},[],{"intervention":852,"totalTrials":131,"cells":853},"Full dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS",{"EARLY_PHASE1":854,"PHASE1":856,"PHASE2":858,"PHASE3":860,"PHASE4":862,"NA":877},{"trials":855,"activeCount":67},[],{"trials":857,"activeCount":67},[],{"trials":859,"activeCount":67},[],{"trials":861,"activeCount":67},[],{"trials":863,"activeCount":67},[864],{"nctId":865,"briefTitle":866,"status":75,"phases":867,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":872,"interventions":873},"NCT05460377","Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine",[59],"2023-07-22","2024-12-01","2022-07-26",1224,[27],[852,874,875,876],"Fractional (1\u002F5) Dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS","Full dose Sabin Inactivated Poliovirus Vaccine produced by BIBP","Fractional (1\u002F5) dose Sabin Inactivated Poliovirus Vaccine produced by BIBP",{"trials":878,"activeCount":67},[],{"intervention":874,"totalTrials":131,"cells":880},{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":887,"PHASE4":889,"NA":895},{"trials":882,"activeCount":67},[],{"trials":884,"activeCount":67},[],{"trials":886,"activeCount":67},[],{"trials":888,"activeCount":67},[],{"trials":890,"activeCount":67},[891],{"nctId":865,"briefTitle":866,"status":75,"phases":892,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":893,"interventions":894},[59],[27],[852,874,875,876],{"trials":896,"activeCount":67},[],{"intervention":875,"totalTrials":131,"cells":898},{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":903,"PHASE3":905,"PHASE4":907,"NA":913},{"trials":900,"activeCount":67},[],{"trials":902,"activeCount":67},[],{"trials":904,"activeCount":67},[],{"trials":906,"activeCount":67},[],{"trials":908,"activeCount":67},[909],{"nctId":865,"briefTitle":866,"status":75,"phases":910,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":911,"interventions":912},[59],[27],[852,874,875,876],{"trials":914,"activeCount":67},[],{"intervention":876,"totalTrials":131,"cells":916},{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":923,"PHASE4":925,"NA":931},{"trials":918,"activeCount":67},[],{"trials":920,"activeCount":67},[],{"trials":922,"activeCount":67},[],{"trials":924,"activeCount":67},[],{"trials":926,"activeCount":67},[927],{"nctId":865,"briefTitle":866,"status":75,"phases":928,"primaryCompletion":868,"completion":869,"start":870,"enrollment":871,"conditions":929,"interventions":930},[59],[27],[852,874,875,876],{"trials":932,"activeCount":67},[],{"intervention":934,"totalTrials":131,"cells":935},"Cotrimoxazole",{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":942,"PHASE4":944,"NA":956},{"trials":937,"activeCount":67},[],{"trials":939,"activeCount":67},[],{"trials":941,"activeCount":67},[],{"trials":943,"activeCount":67},[],{"trials":945,"activeCount":67},[946],{"nctId":947,"briefTitle":948,"status":75,"phases":949,"completion":950,"start":419,"enrollment":951,"conditions":952,"interventions":955},"NCT00137657","Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance",[59],"2003-11",1478,[22,19,36,953,954],"Pneumonia","Opportunistic Infections",[934],{"trials":957,"activeCount":67},[],{"intervention":959,"totalTrials":131,"cells":960},"Hib conjugate vaccine",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":967,"PHASE4":969,"NA":981},{"trials":962,"activeCount":67},[],{"trials":964,"activeCount":67},[],{"trials":966,"activeCount":67},[],{"trials":968,"activeCount":67},[],{"trials":970,"activeCount":67},[971],{"nctId":972,"briefTitle":973,"status":75,"phases":974,"completion":950,"start":975,"enrollment":976,"conditions":977,"interventions":980},"NCT00153556","Study to Eliminate Hib Carriage in Rural Alaska Native Villages",[59],"2001-09",3200,[978,979],"Haemophilus Influenzae Type B","Carrier State",[959],{"trials":982,"activeCount":67},[],{"intervention":984,"totalTrials":131,"cells":985},"Flublok",{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":992,"PHASE4":994,"NA":1009},{"trials":987,"activeCount":67},[],{"trials":989,"activeCount":67},[],{"trials":991,"activeCount":67},[],{"trials":993,"activeCount":67},[],{"trials":995,"activeCount":67},[996],{"nctId":997,"briefTitle":998,"status":75,"phases":999,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1004},"NCT03722589","Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP",[59],"2020-07-31","2018-09-12",944,[30],[984,1005,1006,1007,1008],"Flucelvax","Fluarix","Fluzone","Fluzone High-Dose",{"trials":1010,"activeCount":67},[],{"intervention":1005,"totalTrials":131,"cells":1012},{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1019,"PHASE4":1021,"NA":1027},{"trials":1014,"activeCount":67},[],{"trials":1016,"activeCount":67},[],{"trials":1018,"activeCount":67},[],{"trials":1020,"activeCount":67},[],{"trials":1022,"activeCount":67},[1023],{"nctId":997,"briefTitle":998,"status":75,"phases":1024,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1025,"interventions":1026},[59],[30],[984,1005,1006,1007,1008],{"trials":1028,"activeCount":67},[],{"intervention":1006,"totalTrials":131,"cells":1030},{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1037,"PHASE4":1039,"NA":1045},{"trials":1032,"activeCount":67},[],{"trials":1034,"activeCount":67},[],{"trials":1036,"activeCount":67},[],{"trials":1038,"activeCount":67},[],{"trials":1040,"activeCount":67},[1041],{"nctId":997,"briefTitle":998,"status":75,"phases":1042,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1043,"interventions":1044},[59],[30],[984,1005,1006,1007,1008],{"trials":1046,"activeCount":67},[],{"intervention":1007,"totalTrials":131,"cells":1048},{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1053,"PHASE3":1055,"PHASE4":1057,"NA":1063},{"trials":1050,"activeCount":67},[],{"trials":1052,"activeCount":67},[],{"trials":1054,"activeCount":67},[],{"trials":1056,"activeCount":67},[],{"trials":1058,"activeCount":67},[1059],{"nctId":997,"briefTitle":998,"status":75,"phases":1060,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1061,"interventions":1062},[59],[30],[984,1005,1006,1007,1008],{"trials":1064,"activeCount":67},[],{"intervention":1008,"totalTrials":131,"cells":1066},{"EARLY_PHASE1":1067,"PHASE1":1069,"PHASE2":1071,"PHASE3":1073,"PHASE4":1075,"NA":1081},{"trials":1068,"activeCount":67},[],{"trials":1070,"activeCount":67},[],{"trials":1072,"activeCount":67},[],{"trials":1074,"activeCount":67},[],{"trials":1076,"activeCount":67},[1077],{"nctId":997,"briefTitle":998,"status":75,"phases":1078,"primaryCompletion":1000,"completion":1000,"start":1001,"enrollment":1002,"conditions":1079,"interventions":1080},[59],[30],[984,1005,1006,1007,1008],{"trials":1082,"activeCount":67},[],{"intervention":1084,"totalTrials":131,"cells":1085},"IPV at 14 and 22 weeks of age, Rotarix",{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1092,"PHASE4":1094,"NA":1112},{"trials":1087,"activeCount":67},[],{"trials":1089,"activeCount":67},[],{"trials":1091,"activeCount":67},[],{"trials":1093,"activeCount":67},[],{"trials":1095,"activeCount":67},[1096],{"nctId":1097,"briefTitle":1098,"status":75,"phases":1099,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":1102,"conditions":1103,"interventions":1104},"NCT02847026","Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study",[59],"2017-05","2016-09",1144,[27],[1084,1105,1106,1107,1108,1109,1110,1111],"IPV at 14 and 22 weeks of age, RotaTeq","IPV at 14 and fIPV at 22 weeks, Rotarix","IPV at 14 and fIPV at 22 weeks, RotaTeq","IPV at 6 and fIPV at 22 weeks, Rotarix","IPV at 6 and fIPV at 22 weeks, RotaTeq","fIPV at 6-14-22 weeks of age, Rotarix","fIPV at 6-14-22 weeks of age, RotaTeq",{"trials":1113,"activeCount":67},[],{"intervention":1105,"totalTrials":131,"cells":1115},{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1130},{"trials":1117,"activeCount":67},[],{"trials":1119,"activeCount":67},[],{"trials":1121,"activeCount":67},[],{"trials":1123,"activeCount":67},[],{"trials":1125,"activeCount":67},[1126],{"nctId":1097,"briefTitle":1098,"status":75,"phases":1127,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":1102,"conditions":1128,"interventions":1129},[59],[27],[1084,1105,1106,1107,1108,1109,1110,1111],{"trials":1131,"activeCount":67},[],{"intervention":1106,"totalTrials":131,"cells":1133},{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1138,"PHASE3":1140,"PHASE4":1142,"NA":1148},{"trials":1135,"activeCount":67},[],{"trials":1137,"activeCount":67},[],{"trials":1139,"activeCount":67},[],{"trials":1141,"activeCount":67},[],{"trials":1143,"activeCount":67},[1144],{"nctId":1097,"briefTitle":1098,"status":75,"phases":1145,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":1102,"conditions":1146,"interventions":1147},[59],[27],[1084,1105,1106,1107,1108,1109,1110,1111],{"trials":1149,"activeCount":67},[],{"intervention":1107,"totalTrials":131,"cells":1151},{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1156,"PHASE3":1158,"PHASE4":1160,"NA":1166},{"trials":1153,"activeCount":67},[],{"trials":1155,"activeCount":67},[],{"trials":1157,"activeCount":67},[],{"trials":1159,"activeCount":67},[],{"trials":1161,"activeCount":67},[1162],{"nctId":1097,"briefTitle":1098,"status":75,"phases":1163,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":1102,"conditions":1164,"interventions":1165},[59],[27],[1084,1105,1106,1107,1108,1109,1110,1111],{"trials":1167,"activeCount":67},[],{"intervention":1108,"totalTrials":131,"cells":1169},{"EARLY_PHASE1":1170,"PHASE1":1172,"PHASE2":1174,"PHASE3":1176,"PHASE4":1178,"NA":1184},{"trials":1171,"activeCount":67},[],{"trials":1173,"activeCount":67},[],{"trials":1175,"activeCount":67},[],{"trials":1177,"activeCount":67},[],{"trials":1179,"activeCount":67},[1180],{"nctId":1097,"briefTitle":1098,"status":75,"phases":1181,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":1102,"conditions":1182,"interventions":1183},[59],[27],[1084,1105,1106,1107,1108,1109,1110,1111],{"trials":1185,"activeCount":67},[],{"intervention":1109,"totalTrials":131,"cells":1187},{"EARLY_PHASE1":1188,"PHASE1":1190,"PHASE2":1192,"PHASE3":1194,"PHASE4":1196,"NA":1202},{"trials":1189,"activeCount":67},[],{"trials":1191,"activeCount":67},[],{"trials":1193,"activeCount":67},[],{"trials":1195,"activeCount":67},[],{"trials":1197,"activeCount":67},[1198],{"nctId":1097,"briefTitle":1098,"status":75,"phases":1199,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":1102,"conditions":1200,"interventions":1201},[59],[27],[1084,1105,1106,1107,1108,1109,1110,1111],{"trials":1203,"activeCount":67},[],{"intervention":1110,"totalTrials":131,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1212,"PHASE4":1214,"NA":1220},{"trials":1207,"activeCount":67},[],{"trials":1209,"activeCount":67},[],{"trials":1211,"activeCount":67},[],{"trials":1213,"activeCount":67},[],{"trials":1215,"activeCount":67},[1216],{"nctId":1097,"briefTitle":1098,"status":75,"phases":1217,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":1102,"conditions":1218,"interventions":1219},[59],[27],[1084,1105,1106,1107,1108,1109,1110,1111],{"trials":1221,"activeCount":67},[],{"intervention":1111,"totalTrials":131,"cells":1223},{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1230,"PHASE4":1232,"NA":1238},{"trials":1225,"activeCount":67},[],{"trials":1227,"activeCount":67},[],{"trials":1229,"activeCount":67},[],{"trials":1231,"activeCount":67},[],{"trials":1233,"activeCount":67},[1234],{"nctId":1097,"briefTitle":1098,"status":75,"phases":1235,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":1102,"conditions":1236,"interventions":1237},[59],[27],[1084,1105,1106,1107,1108,1109,1110,1111],{"trials":1239,"activeCount":67},[],{"intervention":1241,"totalTrials":131,"cells":1242},"AQAS",{"EARLY_PHASE1":1243,"PHASE1":1245,"PHASE2":1247,"PHASE3":1249,"PHASE4":1251,"NA":1261},{"trials":1244,"activeCount":67},[],{"trials":1246,"activeCount":67},[],{"trials":1248,"activeCount":67},[],{"trials":1250,"activeCount":67},[],{"trials":1252,"activeCount":67},[1253],{"nctId":1254,"briefTitle":1255,"status":75,"phases":1256,"primaryCompletion":88,"completion":88,"start":1257,"enrollment":1258,"conditions":1259,"interventions":1260},"NCT00425763","Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria",[59],"2007-05",110,[19],[1241],{"trials":1262,"activeCount":67},[],{"intervention":1264,"totalTrials":131,"cells":1265},"Depo-Medroxyprogesterone Acetate",{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1270,"PHASE3":1272,"PHASE4":1274,"NA":1287},{"trials":1267,"activeCount":67},[],{"trials":1269,"activeCount":67},[],{"trials":1271,"activeCount":67},[],{"trials":1273,"activeCount":67},[],{"trials":1275,"activeCount":67},[1276],{"nctId":1277,"briefTitle":1278,"status":75,"phases":1279,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":1283,"interventions":1285},"NCT02103660","Clinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected Women",[59],"2017-03-31","2014-04-08",131,[22,1284],"Contraception",[1264,1286],"Progestin Contraceptive",{"trials":1288,"activeCount":67},[],{"intervention":1286,"totalTrials":131,"cells":1290},{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1295,"PHASE3":1297,"PHASE4":1299,"NA":1305},{"trials":1292,"activeCount":67},[],{"trials":1294,"activeCount":67},[],{"trials":1296,"activeCount":67},[],{"trials":1298,"activeCount":67},[],{"trials":1300,"activeCount":67},[1301],{"nctId":1277,"briefTitle":1278,"status":75,"phases":1302,"primaryCompletion":1280,"completion":1280,"start":1281,"enrollment":1282,"conditions":1303,"interventions":1304},[59],[22,1284],[1264,1286],{"trials":1306,"activeCount":67},[],{"intervention":1308,"totalTrials":131,"cells":1309},"Yellow Fever 17DD Vaccine",{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1316,"PHASE4":1318,"NA":1330},{"trials":1311,"activeCount":67},[],{"trials":1313,"activeCount":67},[],{"trials":1315,"activeCount":67},[],{"trials":1317,"activeCount":67},[],{"trials":1319,"activeCount":67},[1320],{"nctId":1321,"briefTitle":1322,"status":75,"phases":1323,"primaryCompletion":1324,"completion":1324,"start":1325,"enrollment":1326,"conditions":1327,"interventions":1329},"NCT03725618","Immunogenicity of Fractional One-fifth and One-half Doses of Yellow Fever Vaccine Compared to Full Dose in Children 9-23 Months Old",[59],"2021-09-01","2018-11-01",1788,[1328],"Yellow Fever",[1308],{"trials":1331,"activeCount":67},[],{"intervention":1333,"totalTrials":131,"cells":1334},"Measles, mumps and rubella Combined Vaccine, Live",{"EARLY_PHASE1":1335,"PHASE1":1337,"PHASE2":1339,"PHASE3":1341,"PHASE4":1343,"NA":1359},{"trials":1336,"activeCount":67},[],{"trials":1338,"activeCount":67},[],{"trials":1340,"activeCount":67},[],{"trials":1342,"activeCount":67},[],{"trials":1344,"activeCount":67},[1345],{"nctId":1346,"briefTitle":1347,"status":75,"phases":1348,"primaryCompletion":1349,"completion":1350,"start":1351,"enrollment":1352,"conditions":1353,"interventions":1358},"NCT03160820","Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine",[59],"2016-12","2017-02","2016-03",873,[1354,1355,1356,1357],"Measles","Mumps","Rubella","Adverse Event Following Immunisation",[1333],{"trials":1360,"activeCount":67},[],{"intervention":1362,"totalTrials":131,"cells":1363},"Measles-rubella (MR) vaccine at 6 months of age",{"EARLY_PHASE1":1364,"PHASE1":1366,"PHASE2":1368,"PHASE3":1370,"PHASE4":1372,"NA":1385},{"trials":1365,"activeCount":67},[],{"trials":1367,"activeCount":67},[],{"trials":1369,"activeCount":67},[],{"trials":1371,"activeCount":67},[],{"trials":1373,"activeCount":67},[1374],{"nctId":1375,"briefTitle":1376,"status":75,"phases":1377,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":1380,"conditions":1381,"interventions":1383},"NCT03071575","Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age",[59],"2018-03-18","2017-03-09",637,[1354,1356,1382],"Rubella Syndrome, Congenital",[1362,1384],"Measles-rubella (MR) vaccine at 9 months of age",{"trials":1386,"activeCount":67},[],{"intervention":1384,"totalTrials":131,"cells":1388},{"EARLY_PHASE1":1389,"PHASE1":1391,"PHASE2":1393,"PHASE3":1395,"PHASE4":1397,"NA":1403},{"trials":1390,"activeCount":67},[],{"trials":1392,"activeCount":67},[],{"trials":1394,"activeCount":67},[],{"trials":1396,"activeCount":67},[],{"trials":1398,"activeCount":67},[1399],{"nctId":1375,"briefTitle":1376,"status":75,"phases":1400,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":1380,"conditions":1401,"interventions":1402},[59],[1354,1356,1382],[1362,1384],{"trials":1404,"activeCount":67},[],{"intervention":1406,"totalTrials":131,"cells":1407},"Flublok™ Quadrivalent by Sanofi, Inc.",{"EARLY_PHASE1":1408,"PHASE1":1410,"PHASE2":1412,"PHASE3":1414,"PHASE4":1416,"NA":1429},{"trials":1409,"activeCount":67},[],{"trials":1411,"activeCount":67},[],{"trials":1413,"activeCount":67},[],{"trials":1415,"activeCount":67},[],{"trials":1417,"activeCount":67},[1418],{"nctId":1419,"briefTitle":1420,"status":75,"phases":1421,"primaryCompletion":1422,"completion":1423,"start":1424,"enrollment":1425,"conditions":1426,"interventions":1427},"NCT04523324","Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel",[59],"2020-01-30","2022-08-30","2019-10-31",577,[30],[1406,1428],"VaxigripTetra™ by Sanofi, Inc.",{"trials":1430,"activeCount":67},[],{"intervention":1428,"totalTrials":131,"cells":1432},{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1439,"PHASE4":1441,"NA":1447},{"trials":1434,"activeCount":67},[],{"trials":1436,"activeCount":67},[],{"trials":1438,"activeCount":67},[],{"trials":1440,"activeCount":67},[],{"trials":1442,"activeCount":67},[1443],{"nctId":1419,"briefTitle":1420,"status":75,"phases":1444,"primaryCompletion":1422,"completion":1423,"start":1424,"enrollment":1425,"conditions":1445,"interventions":1446},[59],[30],[1406,1428],{"trials":1448,"activeCount":67},[],{"intervention":573,"totalTrials":131,"cells":1450},{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1455,"PHASE3":1457,"PHASE4":1459,"NA":1465},{"trials":1452,"activeCount":67},[],{"trials":1454,"activeCount":67},[],{"trials":1456,"activeCount":67},[],{"trials":1458,"activeCount":67},[],{"trials":1460,"activeCount":67},[1461],{"nctId":566,"briefTitle":567,"status":75,"phases":1462,"primaryCompletion":558,"completion":558,"start":559,"enrollment":569,"conditions":1463,"interventions":1464},[59],[562],[572,573,574,564,575],{"trials":1466,"activeCount":67},[],{"intervention":575,"totalTrials":131,"cells":1468},{"EARLY_PHASE1":1469,"PHASE1":1471,"PHASE2":1473,"PHASE3":1475,"PHASE4":1477,"NA":1483},{"trials":1470,"activeCount":67},[],{"trials":1472,"activeCount":67},[],{"trials":1474,"activeCount":67},[],{"trials":1476,"activeCount":67},[],{"trials":1478,"activeCount":67},[1479],{"nctId":566,"briefTitle":567,"status":75,"phases":1480,"primaryCompletion":558,"completion":558,"start":559,"enrollment":569,"conditions":1481,"interventions":1482},[59],[562],[572,573,574,564,575],{"trials":1484,"activeCount":67},[],{"intervention":1486,"totalTrials":131,"cells":1487},"mOPV2 at 6 and 7 weeks of age",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1494,"PHASE4":1496,"NA":1509},{"trials":1489,"activeCount":67},[],{"trials":1491,"activeCount":67},[],{"trials":1493,"activeCount":67},[],{"trials":1495,"activeCount":67},[],{"trials":1497,"activeCount":67},[1498],{"nctId":1499,"briefTitle":1500,"status":75,"phases":1501,"primaryCompletion":1502,"completion":1502,"start":651,"enrollment":1503,"conditions":1504,"interventions":1505},"NCT02643368","Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine",[59],"2016-02",760,[27],[1486,1506,1507,1508],"mOPV2 at 6 and 8 weeks of age","mOPV2 at 6 and 10 weeks of age","IPV at 6 weeks of age",{"trials":1510,"activeCount":67},[],{"intervention":1506,"totalTrials":131,"cells":1512},{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1527},{"trials":1514,"activeCount":67},[],{"trials":1516,"activeCount":67},[],{"trials":1518,"activeCount":67},[],{"trials":1520,"activeCount":67},[],{"trials":1522,"activeCount":67},[1523],{"nctId":1499,"briefTitle":1500,"status":75,"phases":1524,"primaryCompletion":1502,"completion":1502,"start":651,"enrollment":1503,"conditions":1525,"interventions":1526},[59],[27],[1486,1506,1507,1508],{"trials":1528,"activeCount":67},[],{"intervention":1507,"totalTrials":131,"cells":1530},{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1535,"PHASE3":1537,"PHASE4":1539,"NA":1545},{"trials":1532,"activeCount":67},[],{"trials":1534,"activeCount":67},[],{"trials":1536,"activeCount":67},[],{"trials":1538,"activeCount":67},[],{"trials":1540,"activeCount":67},[1541],{"nctId":1499,"briefTitle":1500,"status":75,"phases":1542,"primaryCompletion":1502,"completion":1502,"start":651,"enrollment":1503,"conditions":1543,"interventions":1544},[59],[27],[1486,1506,1507,1508],{"trials":1546,"activeCount":67},[],{"intervention":1508,"totalTrials":131,"cells":1548},{"EARLY_PHASE1":1549,"PHASE1":1551,"PHASE2":1553,"PHASE3":1555,"PHASE4":1557,"NA":1563},{"trials":1550,"activeCount":67},[],{"trials":1552,"activeCount":67},[],{"trials":1554,"activeCount":67},[],{"trials":1556,"activeCount":67},[],{"trials":1558,"activeCount":67},[1559],{"nctId":1499,"briefTitle":1500,"status":75,"phases":1560,"primaryCompletion":1502,"completion":1502,"start":651,"enrollment":1503,"conditions":1561,"interventions":1562},[59],[27],[1486,1506,1507,1508],{"trials":1564,"activeCount":67},[],{"intervention":666,"totalTrials":131,"cells":1566},{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1573,"PHASE4":1575,"NA":1581},{"trials":1568,"activeCount":67},[],{"trials":1570,"activeCount":67},[],{"trials":1572,"activeCount":67},[],{"trials":1574,"activeCount":67},[],{"trials":1576,"activeCount":67},[1577],{"nctId":658,"briefTitle":659,"status":75,"phases":1578,"primaryCompletion":661,"completion":661,"start":662,"enrollment":663,"conditions":1579,"interventions":1580},[59],[27],[666,635,667],{"trials":1582,"activeCount":67},[],{"intervention":667,"totalTrials":131,"cells":1584},{"EARLY_PHASE1":1585,"PHASE1":1587,"PHASE2":1589,"PHASE3":1591,"PHASE4":1593,"NA":1599},{"trials":1586,"activeCount":67},[],{"trials":1588,"activeCount":67},[],{"trials":1590,"activeCount":67},[],{"trials":1592,"activeCount":67},[],{"trials":1594,"activeCount":67},[1595],{"nctId":658,"briefTitle":659,"status":75,"phases":1596,"primaryCompletion":661,"completion":661,"start":662,"enrollment":663,"conditions":1597,"interventions":1598},[59],[27],[666,635,667],{"trials":1600,"activeCount":67},[],{"intervention":1602,"totalTrials":131,"cells":1603},"Measles-Rubella combined vaccine",{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1610,"PHASE4":1612,"NA":1625},{"trials":1605,"activeCount":67},[],{"trials":1607,"activeCount":67},[],{"trials":1609,"activeCount":67},[],{"trials":1611,"activeCount":67},[],{"trials":1613,"activeCount":67},[1614],{"nctId":1615,"briefTitle":1616,"status":75,"phases":1617,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":1620,"conditions":1621,"interventions":1623},"NCT02643433","Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines",[59],"2016-06","2015-08",1043,[1354,1356,1622],"Japanese Encephalitis",[1602,1624],"Japanese Encephalitis alive vaccine",{"trials":1626,"activeCount":67},[],{"intervention":1624,"totalTrials":131,"cells":1628},{"EARLY_PHASE1":1629,"PHASE1":1631,"PHASE2":1633,"PHASE3":1635,"PHASE4":1637,"NA":1643},{"trials":1630,"activeCount":67},[],{"trials":1632,"activeCount":67},[],{"trials":1634,"activeCount":67},[],{"trials":1636,"activeCount":67},[],{"trials":1638,"activeCount":67},[1639],{"nctId":1615,"briefTitle":1616,"status":75,"phases":1640,"primaryCompletion":1618,"completion":1618,"start":1619,"enrollment":1620,"conditions":1641,"interventions":1642},[59],[1354,1356,1622],[1602,1624],{"trials":1644,"activeCount":67},[],{"intervention":423,"totalTrials":131,"cells":1646},{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1653,"PHASE4":1655,"NA":1661},{"trials":1648,"activeCount":67},[],{"trials":1650,"activeCount":67},[],{"trials":1652,"activeCount":67},[],{"trials":1654,"activeCount":67},[],{"trials":1656,"activeCount":67},[1657],{"nctId":416,"briefTitle":417,"status":75,"phases":1658,"completion":419,"start":420,"enrollment":23,"conditions":1659,"interventions":1660},[59],[16,25],[423,48],{"trials":1662,"activeCount":67},[],{"intervention":1664,"totalTrials":131,"cells":1665},"meningococcal conjugate vaccine",{"EARLY_PHASE1":1666,"PHASE1":1668,"PHASE2":1670,"PHASE3":1672,"PHASE4":1674,"NA":1685},{"trials":1667,"activeCount":67},[],{"trials":1669,"activeCount":67},[],{"trials":1671,"activeCount":67},[],{"trials":1673,"activeCount":67},[],{"trials":1675,"activeCount":67},[1676],{"nctId":1677,"briefTitle":1678,"status":75,"phases":1679,"completion":1257,"start":1680,"enrollment":1681,"conditions":1682,"interventions":1684},"NCT00119080","Effect of Meningococcal Conjugate Vaccine on Meningococcal Carriage",[59],"2006-08",4000,[1683],"Meningitis",[1664],{"trials":1686,"activeCount":67},[],{"intervention":1688,"totalTrials":131,"cells":1689},"Sulfadoxine-pyrimethamine\u002Ffolic acid",{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1694,"PHASE3":1696,"PHASE4":1698,"NA":1708},{"trials":1691,"activeCount":67},[],{"trials":1693,"activeCount":67},[],{"trials":1695,"activeCount":67},[],{"trials":1697,"activeCount":67},[],{"trials":1699,"activeCount":67},[1700],{"nctId":1701,"briefTitle":1702,"status":75,"phases":1703,"primaryCompletion":79,"completion":79,"start":950,"enrollment":1704,"conditions":1705,"interventions":1706},"NCT00130065","The Effect of Folic Acid on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya",[59],600,[19],[1688,1707],"Sulfadoxine-pyrimethamine\u002Fplacebo",{"trials":1709,"activeCount":67},[],{"intervention":1707,"totalTrials":131,"cells":1711},{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1716,"PHASE3":1718,"PHASE4":1720,"NA":1726},{"trials":1713,"activeCount":67},[],{"trials":1715,"activeCount":67},[],{"trials":1717,"activeCount":67},[],{"trials":1719,"activeCount":67},[],{"trials":1721,"activeCount":67},[1722],{"nctId":1701,"briefTitle":1702,"status":75,"phases":1723,"primaryCompletion":79,"completion":79,"start":950,"enrollment":1704,"conditions":1724,"interventions":1725},[59],[19],[1688,1707],{"trials":1727,"activeCount":67},[],{"intervention":1729,"totalTrials":131,"cells":1730},"Vaccine",{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1735,"PHASE3":1737,"PHASE4":1739,"NA":1757},{"trials":1732,"activeCount":67},[],{"trials":1734,"activeCount":67},[],{"trials":1736,"activeCount":67},[],{"trials":1738,"activeCount":67},[],{"trials":1740,"activeCount":67},[1741],{"nctId":1742,"briefTitle":1743,"status":1744,"phases":1745,"primaryCompletion":1746,"completion":1747,"start":1748,"enrollment":1749,"conditions":1750,"interventions":1756},"NCT05298800","Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23","UNKNOWN",[59],"2022-12-31","2023-12-31","2021-10-08",3000,[1751,1752,1753,1754,1755],"Safety","Immunogenicity, Vaccine","COVID-19 Vaccines","Influenza Vaccines","Pneumococcal Vaccines",[1729],{"trials":1758,"activeCount":67},[],{"intervention":1760,"totalTrials":131,"cells":1761},"Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age",{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1768,"PHASE4":1770,"NA":1786},{"trials":1763,"activeCount":67},[],{"trials":1765,"activeCount":67},[],{"trials":1767,"activeCount":67},[],{"trials":1769,"activeCount":67},[],{"trials":1771,"activeCount":67},[1772],{"nctId":1773,"briefTitle":1774,"status":75,"phases":1775,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":1778,"conditions":1779,"interventions":1780},"NCT03202719","Duration of IPV Priming and Antibody Decay",[59],"2019-10-01","2017-11-05",1645,[27],[1760,1781,1782,1783,1784,1785],"Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age","Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age","Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age","Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age","Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age",{"trials":1787,"activeCount":67},[],{"intervention":1781,"totalTrials":131,"cells":1789},{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1796,"PHASE4":1798,"NA":1804},{"trials":1791,"activeCount":67},[],{"trials":1793,"activeCount":67},[],{"trials":1795,"activeCount":67},[],{"trials":1797,"activeCount":67},[],{"trials":1799,"activeCount":67},[1800],{"nctId":1773,"briefTitle":1774,"status":75,"phases":1801,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":1778,"conditions":1802,"interventions":1803},[59],[27],[1760,1781,1782,1783,1784,1785],{"trials":1805,"activeCount":67},[],{"intervention":1782,"totalTrials":131,"cells":1807},{"EARLY_PHASE1":1808,"PHASE1":1810,"PHASE2":1812,"PHASE3":1814,"PHASE4":1816,"NA":1822},{"trials":1809,"activeCount":67},[],{"trials":1811,"activeCount":67},[],{"trials":1813,"activeCount":67},[],{"trials":1815,"activeCount":67},[],{"trials":1817,"activeCount":67},[1818],{"nctId":1773,"briefTitle":1774,"status":75,"phases":1819,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":1778,"conditions":1820,"interventions":1821},[59],[27],[1760,1781,1782,1783,1784,1785],{"trials":1823,"activeCount":67},[],{"intervention":1783,"totalTrials":131,"cells":1825},{"EARLY_PHASE1":1826,"PHASE1":1828,"PHASE2":1830,"PHASE3":1832,"PHASE4":1834,"NA":1840},{"trials":1827,"activeCount":67},[],{"trials":1829,"activeCount":67},[],{"trials":1831,"activeCount":67},[],{"trials":1833,"activeCount":67},[],{"trials":1835,"activeCount":67},[1836],{"nctId":1773,"briefTitle":1774,"status":75,"phases":1837,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":1778,"conditions":1838,"interventions":1839},[59],[27],[1760,1781,1782,1783,1784,1785],{"trials":1841,"activeCount":67},[],{"intervention":1784,"totalTrials":131,"cells":1843},{"EARLY_PHASE1":1844,"PHASE1":1846,"PHASE2":1848,"PHASE3":1850,"PHASE4":1852,"NA":1858},{"trials":1845,"activeCount":67},[],{"trials":1847,"activeCount":67},[],{"trials":1849,"activeCount":67},[],{"trials":1851,"activeCount":67},[],{"trials":1853,"activeCount":67},[1854],{"nctId":1773,"briefTitle":1774,"status":75,"phases":1855,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":1778,"conditions":1856,"interventions":1857},[59],[27],[1760,1781,1782,1783,1784,1785],{"trials":1859,"activeCount":67},[],{"intervention":1785,"totalTrials":131,"cells":1861},{"EARLY_PHASE1":1862,"PHASE1":1864,"PHASE2":1866,"PHASE3":1868,"PHASE4":1870,"NA":1876},{"trials":1863,"activeCount":67},[],{"trials":1865,"activeCount":67},[],{"trials":1867,"activeCount":67},[],{"trials":1869,"activeCount":67},[],{"trials":1871,"activeCount":67},[1872],{"nctId":1773,"briefTitle":1774,"status":75,"phases":1873,"primaryCompletion":1776,"completion":1776,"start":1777,"enrollment":1778,"conditions":1874,"interventions":1875},[59],[27],[1760,1781,1782,1783,1784,1785],{"trials":1877,"activeCount":67},[],{"intervention":1879,"totalTrials":131,"cells":1880},"artesunate-amodiaquine",{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1885,"PHASE3":1887,"PHASE4":1889,"NA":1902},{"trials":1882,"activeCount":67},[],{"trials":1884,"activeCount":67},[],{"trials":1886,"activeCount":67},[],{"trials":1888,"activeCount":67},[],{"trials":1890,"activeCount":67},[1891],{"nctId":1892,"briefTitle":1893,"status":75,"phases":1894,"primaryCompletion":1895,"completion":1895,"start":1896,"enrollment":1897,"conditions":1898,"interventions":1900},"NCT02637128","In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria",[59],"2014-07","2014-03",452,[1899],"MALARIA, FALCIPARUM",[1901,1879],"artemether-lumefantrine",{"trials":1903,"activeCount":67},[],{"intervention":1905,"totalTrials":131,"cells":1906},"sulfadoxine-pyrimethamine plus artesunate",{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1911,"PHASE3":1913,"PHASE4":1915,"NA":1929},{"trials":1908,"activeCount":67},[],{"trials":1910,"activeCount":67},[],{"trials":1912,"activeCount":67},[],{"trials":1914,"activeCount":67},[],{"trials":1916,"activeCount":67},[1917],{"nctId":1918,"briefTitle":1919,"status":75,"phases":1920,"primaryCompletion":1921,"completion":1921,"start":1922,"enrollment":1923,"conditions":1924,"interventions":1926},"NCT00140361","Efficacy of Sulphadoxine-pyrimethamine and Artemisinin-containing Combination Therapy for Malaria",[59],"2008-01","2000-01",390,[1925],"Malaria (Uncomplicated)",[1927,1905,1928],"Sulfadoxine-pyrimethamine","lumefantrine plus artemether",{"trials":1930,"activeCount":67},[],{"intervention":1928,"totalTrials":131,"cells":1932},{"EARLY_PHASE1":1933,"PHASE1":1935,"PHASE2":1937,"PHASE3":1939,"PHASE4":1941,"NA":1947},{"trials":1934,"activeCount":67},[],{"trials":1936,"activeCount":67},[],{"trials":1938,"activeCount":67},[],{"trials":1940,"activeCount":67},[],{"trials":1942,"activeCount":67},[1943],{"nctId":1918,"briefTitle":1919,"status":75,"phases":1944,"primaryCompletion":1921,"completion":1921,"start":1922,"enrollment":1923,"conditions":1945,"interventions":1946},[59],[1925],[1927,1905,1928],{"trials":1948,"activeCount":67},[],{"intervention":1950,"totalTrials":131,"cells":1951},"Anthrax Vaccine Adsorbed",{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1956,"PHASE3":1958,"PHASE4":1960,"NA":1973},{"trials":1953,"activeCount":67},[],{"trials":1955,"activeCount":67},[],{"trials":1957,"activeCount":67},[],{"trials":1959,"activeCount":67},[],{"trials":1961,"activeCount":67},[1962],{"nctId":1963,"briefTitle":1964,"status":75,"phases":1965,"primaryCompletion":1966,"completion":1966,"start":1967,"enrollment":1968,"conditions":1969,"interventions":1971},"NCT00119067","Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change",[59],"2010-02","2002-05",1564,[1970],"Healthy",[1950,1972],"Saline",{"trials":1974,"activeCount":67},[],{"intervention":1972,"totalTrials":131,"cells":1976},{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1981,"PHASE3":1983,"PHASE4":1985,"NA":1991},{"trials":1978,"activeCount":67},[],{"trials":1980,"activeCount":67},[],{"trials":1982,"activeCount":67},[],{"trials":1984,"activeCount":67},[],{"trials":1986,"activeCount":67},[1987],{"nctId":1963,"briefTitle":1964,"status":75,"phases":1988,"primaryCompletion":1966,"completion":1966,"start":1967,"enrollment":1968,"conditions":1989,"interventions":1990},[59],[1970],[1950,1972],{"trials":1992,"activeCount":67},[],{"intervention":1994,"totalTrials":131,"cells":1995},"Intradermal vaccine",{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2002,"PHASE4":2004,"NA":2017},{"trials":1997,"activeCount":67},[],{"trials":1999,"activeCount":67},[],{"trials":2001,"activeCount":67},[],{"trials":2003,"activeCount":67},[],{"trials":2005,"activeCount":67},[2006],{"nctId":2007,"briefTitle":2008,"status":75,"phases":2009,"primaryCompletion":2010,"completion":2011,"start":2012,"enrollment":2013,"conditions":2014,"interventions":2015},"NCT01538940","Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand",[59],"2013-09-09","2015-10","2011-11-01",415,[30],[1994,2016],"Intramuscular vaccine",{"trials":2018,"activeCount":67},[],{"intervention":2016,"totalTrials":131,"cells":2020},{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2027,"PHASE4":2029,"NA":2035},{"trials":2022,"activeCount":67},[],{"trials":2024,"activeCount":67},[],{"trials":2026,"activeCount":67},[],{"trials":2028,"activeCount":67},[],{"trials":2030,"activeCount":67},[2031],{"nctId":2007,"briefTitle":2008,"status":75,"phases":2032,"primaryCompletion":2010,"completion":2011,"start":2012,"enrollment":2013,"conditions":2033,"interventions":2034},[59],[30],[1994,2016],{"trials":2036,"activeCount":67},[],{"intervention":2038,"totalTrials":131,"cells":2039},"sulfadoxine\u002Fpyrimethamine",{"EARLY_PHASE1":2040,"PHASE1":2042,"PHASE2":2044,"PHASE3":2046,"PHASE4":2048,"NA":2060},{"trials":2041,"activeCount":67},[],{"trials":2043,"activeCount":67},[],{"trials":2045,"activeCount":67},[],{"trials":2047,"activeCount":67},[],{"trials":2049,"activeCount":67},[2050],{"nctId":2051,"briefTitle":2052,"status":75,"phases":2053,"primaryCompletion":2054,"completion":2054,"start":2055,"enrollment":2056,"conditions":2057,"interventions":2058},"NCT00164255","Efficacy of Combination Therapy for Prevention of Effects of Malaria During Pregnancy",[59],"2009-06","2003-01",1614,[19],[2038,2059],"sulfadoxine\u002Fpyrimethamine plus artesunate",{"trials":2061,"activeCount":67},[],{"intervention":2059,"totalTrials":131,"cells":2063},{"EARLY_PHASE1":2064,"PHASE1":2066,"PHASE2":2068,"PHASE3":2070,"PHASE4":2072,"NA":2078},{"trials":2065,"activeCount":67},[],{"trials":2067,"activeCount":67},[],{"trials":2069,"activeCount":67},[],{"trials":2071,"activeCount":67},[],{"trials":2073,"activeCount":67},[2074],{"nctId":2051,"briefTitle":2052,"status":75,"phases":2075,"primaryCompletion":2054,"completion":2054,"start":2055,"enrollment":2056,"conditions":2076,"interventions":2077},[59],[19],[2038,2059],{"trials":2079,"activeCount":67},[],{"intervention":2081,"totalTrials":131,"cells":2082},"Oseltamivir phosphate suspension",{"EARLY_PHASE1":2083,"PHASE1":2085,"PHASE2":2087,"PHASE3":2089,"PHASE4":2091,"NA":2103},{"trials":2084,"activeCount":67},[],{"trials":2086,"activeCount":67},[],{"trials":2088,"activeCount":67},[],{"trials":2090,"activeCount":67},[],{"trials":2092,"activeCount":67},[2093],{"nctId":2094,"briefTitle":2095,"status":724,"phases":2096,"primaryCompletion":2097,"completion":2097,"start":2098,"enrollment":2099,"conditions":2100,"interventions":2102},"NCT01690637","Panama and El Salvador Children's Oseltamivir Study",[59],"2013-11","2012-09",721,[30,2101],"Human Influenza",[2081],{"trials":2104,"activeCount":67},[],{"intervention":2106,"totalTrials":131,"cells":2107},"Group A: Trivalent Oral Polio Vaccine",{"EARLY_PHASE1":2108,"PHASE1":2110,"PHASE2":2112,"PHASE3":2114,"PHASE4":2128,"NA":2130},{"trials":2109,"activeCount":67},[],{"trials":2111,"activeCount":67},[],{"trials":2113,"activeCount":67},[],{"trials":2115,"activeCount":67},[2116],{"nctId":2117,"briefTitle":2118,"status":75,"phases":2119,"primaryCompletion":2097,"completion":2097,"start":2120,"enrollment":2121,"conditions":2122,"interventions":2123},"NCT01813604","Immunogenicity of Inactivated and Live Polio Vaccines",[58],"2012-11",1206,[27],[2106,2124,2125,2126,2127],"Group B: Bivalent Oral Polio Vaccine","Group C: Inactivated Polio Vaccine","Group D: fractional IPV","Arm E: f-IPV and bOPV",{"trials":2129,"activeCount":67},[],{"trials":2131,"activeCount":67},[],{"intervention":2124,"totalTrials":131,"cells":2133},{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2138,"PHASE3":2140,"PHASE4":2146,"NA":2148},{"trials":2135,"activeCount":67},[],{"trials":2137,"activeCount":67},[],{"trials":2139,"activeCount":67},[],{"trials":2141,"activeCount":67},[2142],{"nctId":2117,"briefTitle":2118,"status":75,"phases":2143,"primaryCompletion":2097,"completion":2097,"start":2120,"enrollment":2121,"conditions":2144,"interventions":2145},[58],[27],[2106,2124,2125,2126,2127],{"trials":2147,"activeCount":67},[],{"trials":2149,"activeCount":67},[],{"intervention":2125,"totalTrials":131,"cells":2151},{"EARLY_PHASE1":2152,"PHASE1":2154,"PHASE2":2156,"PHASE3":2158,"PHASE4":2164,"NA":2166},{"trials":2153,"activeCount":67},[],{"trials":2155,"activeCount":67},[],{"trials":2157,"activeCount":67},[],{"trials":2159,"activeCount":67},[2160],{"nctId":2117,"briefTitle":2118,"status":75,"phases":2161,"primaryCompletion":2097,"completion":2097,"start":2120,"enrollment":2121,"conditions":2162,"interventions":2163},[58],[27],[2106,2124,2125,2126,2127],{"trials":2165,"activeCount":67},[],{"trials":2167,"activeCount":67},[],{"intervention":2126,"totalTrials":131,"cells":2169},{"EARLY_PHASE1":2170,"PHASE1":2172,"PHASE2":2174,"PHASE3":2176,"PHASE4":2182,"NA":2184},{"trials":2171,"activeCount":67},[],{"trials":2173,"activeCount":67},[],{"trials":2175,"activeCount":67},[],{"trials":2177,"activeCount":67},[2178],{"nctId":2117,"briefTitle":2118,"status":75,"phases":2179,"primaryCompletion":2097,"completion":2097,"start":2120,"enrollment":2121,"conditions":2180,"interventions":2181},[58],[27],[2106,2124,2125,2126,2127],{"trials":2183,"activeCount":67},[],{"trials":2185,"activeCount":67},[],{"intervention":2127,"totalTrials":131,"cells":2187},{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2194,"PHASE4":2200,"NA":2202},{"trials":2189,"activeCount":67},[],{"trials":2191,"activeCount":67},[],{"trials":2193,"activeCount":67},[],{"trials":2195,"activeCount":67},[2196],{"nctId":2117,"briefTitle":2118,"status":75,"phases":2197,"primaryCompletion":2097,"completion":2097,"start":2120,"enrollment":2121,"conditions":2198,"interventions":2199},[58],[27],[2106,2124,2125,2126,2127],{"trials":2201,"activeCount":67},[],{"trials":2203,"activeCount":67},[],{"intervention":2205,"totalTrials":131,"cells":2206},"Ferrous sulphate drops with vitamins A, D, and C",{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2213,"PHASE4":2225,"NA":2227},{"trials":2208,"activeCount":67},[],{"trials":2210,"activeCount":67},[],{"trials":2212,"activeCount":67},[],{"trials":2214,"activeCount":67},[2215],{"nctId":2216,"briefTitle":2217,"status":75,"phases":2218,"primaryCompletion":98,"completion":98,"start":687,"enrollment":2219,"conditions":2220,"interventions":2223},"NCT00136266","Adherence With Iron Sprinkles Among High-Risk Infants",[58],128,[2221,2222],"Anemia","Iron Deficiency",[2205,2224],"Ferrous fumarate sprinkles with vitamins and minerals",{"trials":2226,"activeCount":67},[],{"trials":2228,"activeCount":67},[],{"intervention":2224,"totalTrials":131,"cells":2230},{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2235,"PHASE3":2237,"PHASE4":2243,"NA":2245},{"trials":2232,"activeCount":67},[],{"trials":2234,"activeCount":67},[],{"trials":2236,"activeCount":67},[],{"trials":2238,"activeCount":67},[2239],{"nctId":2216,"briefTitle":2217,"status":75,"phases":2240,"primaryCompletion":98,"completion":98,"start":687,"enrollment":2219,"conditions":2241,"interventions":2242},[58],[2221,2222],[2205,2224],{"trials":2244,"activeCount":67},[],{"trials":2246,"activeCount":67},[],{"intervention":2248,"totalTrials":131,"cells":2249},"rifapentine and moxifloxacin",{"EARLY_PHASE1":2250,"PHASE1":2252,"PHASE2":2254,"PHASE3":2256,"PHASE4":2269,"NA":2271},{"trials":2251,"activeCount":67},[],{"trials":2253,"activeCount":67},[],{"trials":2255,"activeCount":67},[],{"trials":2257,"activeCount":67},[2258],{"nctId":2259,"briefTitle":2260,"status":75,"phases":2261,"primaryCompletion":2262,"completion":2263,"start":2264,"enrollment":2265,"conditions":2266,"interventions":2267},"NCT02410772","TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens",[58],"2020-07","2021-05","2016-01-25",2516,[25],[350,2248,2268],"control",{"trials":2270,"activeCount":67},[],{"trials":2272,"activeCount":67},[],{"intervention":2268,"totalTrials":131,"cells":2274},{"EARLY_PHASE1":2275,"PHASE1":2277,"PHASE2":2279,"PHASE3":2281,"PHASE4":2287,"NA":2289},{"trials":2276,"activeCount":67},[],{"trials":2278,"activeCount":67},[],{"trials":2280,"activeCount":67},[],{"trials":2282,"activeCount":67},[2283],{"nctId":2259,"briefTitle":2260,"status":75,"phases":2284,"primaryCompletion":2262,"completion":2263,"start":2264,"enrollment":2265,"conditions":2285,"interventions":2286},[58],[25],[350,2248,2268],{"trials":2288,"activeCount":67},[],{"trials":2290,"activeCount":67},[],{"intervention":2292,"totalTrials":131,"cells":2293},"Quadrivalent Inactivated Influenza Vaccine",{"EARLY_PHASE1":2294,"PHASE1":2296,"PHASE2":2298,"PHASE3":2300,"PHASE4":2315,"NA":2317},{"trials":2295,"activeCount":67},[],{"trials":2297,"activeCount":67},[],{"trials":2299,"activeCount":67},[],{"trials":2301,"activeCount":67},[2302],{"nctId":2303,"briefTitle":2304,"status":2305,"phases":2306,"primaryCompletion":2307,"completion":2307,"start":2307,"enrollment":67,"conditions":2308,"interventions":2312},"NCT01810731","Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya","WITHDRAWN",[57,58],"2014-04",[2309,22,19,2310,2311],"Influenza, Human","Tetanus","Polio",[2292,2313,2314],"Inactivated Polio Vaccine","Double Dose QIV",{"trials":2316,"activeCount":67},[],{"trials":2318,"activeCount":67},[],{"intervention":2313,"totalTrials":131,"cells":2320},{"EARLY_PHASE1":2321,"PHASE1":2323,"PHASE2":2325,"PHASE3":2327,"PHASE4":2333,"NA":2335},{"trials":2322,"activeCount":67},[],{"trials":2324,"activeCount":67},[],{"trials":2326,"activeCount":67},[],{"trials":2328,"activeCount":67},[2329],{"nctId":2303,"briefTitle":2304,"status":2305,"phases":2330,"primaryCompletion":2307,"completion":2307,"start":2307,"enrollment":67,"conditions":2331,"interventions":2332},[57,58],[2309,22,19,2310,2311],[2292,2313,2314],{"trials":2334,"activeCount":67},[],{"trials":2336,"activeCount":67},[],{"intervention":2314,"totalTrials":131,"cells":2338},{"EARLY_PHASE1":2339,"PHASE1":2341,"PHASE2":2343,"PHASE3":2345,"PHASE4":2351,"NA":2353},{"trials":2340,"activeCount":67},[],{"trials":2342,"activeCount":67},[],{"trials":2344,"activeCount":67},[],{"trials":2346,"activeCount":67},[2347],{"nctId":2303,"briefTitle":2304,"status":2305,"phases":2348,"primaryCompletion":2307,"completion":2307,"start":2307,"enrollment":67,"conditions":2349,"interventions":2350},[57,58],[2309,22,19,2310,2311],[2292,2313,2314],{"trials":2352,"activeCount":67},[],{"trials":2354,"activeCount":67},[],{"intervention":2356,"totalTrials":131,"cells":2357},"Mefloquine Artesunate",{"EARLY_PHASE1":2358,"PHASE1":2360,"PHASE2":2362,"PHASE3":2364,"PHASE4":2375,"NA":2377},{"trials":2359,"activeCount":67},[],{"trials":2361,"activeCount":67},[],{"trials":2363,"activeCount":67},[],{"trials":2365,"activeCount":67},[2366],{"nctId":2367,"briefTitle":2368,"status":2305,"phases":2369,"primaryCompletion":2370,"completion":2370,"start":2371,"enrollment":67,"conditions":2372,"interventions":2374},"NCT01082718","Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection",[57,58],"2010-10","2010-03",[19,2373],"Pregnancy",[2356],{"trials":2376,"activeCount":67},[],{"trials":2378,"activeCount":67},[],{"intervention":2380,"totalTrials":131,"cells":2381},"bOPV\u002FIPV",{"EARLY_PHASE1":2382,"PHASE1":2384,"PHASE2":2386,"PHASE3":2388,"PHASE4":2399,"NA":2401},{"trials":2383,"activeCount":67},[],{"trials":2385,"activeCount":67},[],{"trials":2387,"activeCount":67},[],{"trials":2389,"activeCount":67},[2390],{"nctId":2391,"briefTitle":2392,"status":75,"phases":2393,"primaryCompletion":2394,"completion":1619,"start":2395,"enrollment":2396,"conditions":2397,"interventions":2398},"NCT02291263","Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine",[58],"2015-07","2014-10",738,[27],[2380,2380,2380],{"trials":2400,"activeCount":67},[],{"trials":2402,"activeCount":67},[],{"intervention":2404,"totalTrials":131,"cells":2405},"Standard STD clinic services",{"EARLY_PHASE1":2406,"PHASE1":2408,"PHASE2":2410,"PHASE3":2412,"PHASE4":2424,"NA":2426},{"trials":2407,"activeCount":67},[],{"trials":2409,"activeCount":67},[],{"trials":2411,"activeCount":67},[],{"trials":2413,"activeCount":67},[2414],{"nctId":2415,"briefTitle":2416,"status":75,"phases":2417,"primaryCompletion":2418,"completion":2419,"start":2420,"enrollment":2421,"conditions":2422,"interventions":2423},"NCT00164619","Testing the Effectiveness of VOICES as Implemented by STD & HIV Prevention Agencies in the US and PR",[57,58],"2006-11","2008-03","2001-07",3660,[33],[2404],{"trials":2425,"activeCount":67},[],{"trials":2427,"activeCount":67},[],{"intervention":2429,"totalTrials":131,"cells":2430},"FLUAD Quadrivalent",{"EARLY_PHASE1":2431,"PHASE1":2433,"PHASE2":2435,"PHASE3":2437,"PHASE4":2450,"NA":2452},{"trials":2432,"activeCount":67},[],{"trials":2434,"activeCount":67},[],{"trials":2436,"activeCount":67},[],{"trials":2438,"activeCount":67},[2439],{"nctId":2440,"briefTitle":2441,"status":75,"phases":2442,"primaryCompletion":2443,"completion":2444,"start":2445,"enrollment":2446,"conditions":2447,"interventions":2448},"NCT06054269","Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP",[58],"2023-07-25","2026-05-04","2022-11-04",192,[30],[2429,2449],"FluQuadri",{"trials":2451,"activeCount":67},[],{"trials":2453,"activeCount":67},[],{"intervention":2449,"totalTrials":131,"cells":2455},{"EARLY_PHASE1":2456,"PHASE1":2458,"PHASE2":2460,"PHASE3":2462,"PHASE4":2468,"NA":2470},{"trials":2457,"activeCount":67},[],{"trials":2459,"activeCount":67},[],{"trials":2461,"activeCount":67},[],{"trials":2463,"activeCount":67},[2464],{"nctId":2440,"briefTitle":2441,"status":75,"phases":2465,"primaryCompletion":2443,"completion":2444,"start":2445,"enrollment":2446,"conditions":2466,"interventions":2467},[58],[30],[2429,2449],{"trials":2469,"activeCount":67},[],{"trials":2471,"activeCount":67},[],{"intervention":2473,"totalTrials":131,"cells":2474},"Chlorhexidine",{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2479,"PHASE3":2481,"PHASE4":2495,"NA":2497},{"trials":2476,"activeCount":67},[],{"trials":2478,"activeCount":67},[],{"trials":2480,"activeCount":67},[],{"trials":2482,"activeCount":67},[2483],{"nctId":2484,"briefTitle":2485,"status":1744,"phases":2486,"completion":2487,"start":2488,"enrollment":2489,"conditions":2490,"interventions":2494},"NCT00136370","Prevention of Perinatal Sepsis (PoPS): Evaluation of Chlorhexidine Wipes of Birth Canal and Newborn",[58],"2007-11","2004-04",8000,[2491,2492,2493],"Infant, Newborn, Diseases","Sepsis","Puerperal Infection",[2473],{"trials":2496,"activeCount":67},[],{"trials":2498,"activeCount":67},[],{"intervention":2500,"totalTrials":131,"cells":2501},"zinc",{"EARLY_PHASE1":2502,"PHASE1":2504,"PHASE2":2506,"PHASE3":2508,"PHASE4":2518,"NA":2520},{"trials":2503,"activeCount":67},[],{"trials":2505,"activeCount":67},[],{"trials":2507,"activeCount":67},[],{"trials":2509,"activeCount":67},[2510],{"nctId":2511,"briefTitle":2512,"status":75,"phases":2513,"primaryCompletion":2514,"completion":2514,"start":2515,"enrollment":1749,"conditions":2516,"interventions":2517},"NCT00530829","Impact of Home Zinc Treatment for Acute Diarrhea in Children",[58],"2009-04","2007-10",[36],[2500],{"trials":2519,"activeCount":67},[],{"trials":2521,"activeCount":67},[],{"intervention":2523,"totalTrials":131,"cells":2524},"Tenofovir Disoproxil Fumarate 300 mg daily",{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2529,"PHASE3":2531,"PHASE4":2542,"NA":2544},{"trials":2526,"activeCount":67},[],{"trials":2528,"activeCount":67},[],{"trials":2530,"activeCount":67},[],{"trials":2532,"activeCount":67},[2533],{"nctId":2534,"briefTitle":2535,"status":724,"phases":2536,"completion":2537,"start":558,"enrollment":2538,"conditions":2539,"interventions":2541},"NCT00111150","Botswana Tenofovir Oral HIV Prophylaxis Trial",[57,58],"2007-03",1200,[2540],"HIV Infection",[2523],{"trials":2543,"activeCount":67},[],{"trials":2545,"activeCount":67},[],{"intervention":2547,"totalTrials":131,"cells":2548},"Maternal zidovudine\u002Flamivudine\u002Flopinavir-ritonavir",{"EARLY_PHASE1":2549,"PHASE1":2551,"PHASE2":2553,"PHASE3":2555,"PHASE4":2567,"NA":2569},{"trials":2550,"activeCount":67},[],{"trials":2552,"activeCount":67},[],{"trials":2554,"activeCount":67},[],{"trials":2556,"activeCount":67},[2557],{"nctId":2558,"briefTitle":2559,"status":75,"phases":2560,"primaryCompletion":2561,"completion":2561,"start":2562,"enrollment":2563,"conditions":2564,"interventions":2565},"NCT00164736","Breastfeeding, Antiretroviral, and Nutrition Study",[58],"2010-01","2004-03",2369,[16],[2547,2566],"Infant nevirapine",{"trials":2568,"activeCount":67},[],{"trials":2570,"activeCount":67},[],{"intervention":2566,"totalTrials":131,"cells":2572},{"EARLY_PHASE1":2573,"PHASE1":2575,"PHASE2":2577,"PHASE3":2579,"PHASE4":2585,"NA":2587},{"trials":2574,"activeCount":67},[],{"trials":2576,"activeCount":67},[],{"trials":2578,"activeCount":67},[],{"trials":2580,"activeCount":67},[2581],{"nctId":2558,"briefTitle":2559,"status":75,"phases":2582,"primaryCompletion":2561,"completion":2561,"start":2562,"enrollment":2563,"conditions":2583,"interventions":2584},[58],[16],[2547,2566],{"trials":2586,"activeCount":67},[],{"trials":2588,"activeCount":67},[],{"intervention":2590,"totalTrials":131,"cells":2591},"Antiretroviral therapy",{"EARLY_PHASE1":2592,"PHASE1":2594,"PHASE2":2596,"PHASE3":2598,"PHASE4":2609,"NA":2611},{"trials":2593,"activeCount":67},[],{"trials":2595,"activeCount":67},[],{"trials":2597,"activeCount":67},[],{"trials":2599,"activeCount":67},[2600],{"nctId":2601,"briefTitle":2602,"status":75,"phases":2603,"primaryCompletion":345,"completion":380,"start":2604,"enrollment":2605,"conditions":2606,"interventions":2608},"NCT00144365","Comparison of Facility and Home-based ART Delivery Systems in Uganda",[58],"2005-02",1453,[2607],"AIDS",[2590],{"trials":2610,"activeCount":67},[],{"trials":2612,"activeCount":67},[],{"intervention":2614,"totalTrials":131,"cells":2615},"isoniazid and rifapentine",{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2622,"PHASE4":2632,"NA":2634},{"trials":2617,"activeCount":67},[],{"trials":2619,"activeCount":67},[],{"trials":2621,"activeCount":67},[],{"trials":2623,"activeCount":67},[2624],{"nctId":2625,"briefTitle":2626,"status":75,"phases":2627,"primaryCompletion":2395,"completion":2395,"start":2098,"enrollment":2628,"conditions":2629,"interventions":2631},"NCT01582711","Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT",[58],1002,[2630],"Latent Tuberculosis Infection",[2614],{"trials":2633,"activeCount":67},[],{"trials":2635,"activeCount":67},[],{"intervention":2637,"totalTrials":131,"cells":2638},"RPT + INH once weekly for 3 months given by DOT",{"EARLY_PHASE1":2639,"PHASE1":2641,"PHASE2":2643,"PHASE3":2645,"PHASE4":2657,"NA":2659},{"trials":2640,"activeCount":67},[],{"trials":2642,"activeCount":67},[],{"trials":2644,"activeCount":67},[],{"trials":2646,"activeCount":67},[2647],{"nctId":2648,"briefTitle":2649,"status":75,"phases":2650,"primaryCompletion":2370,"completion":2651,"start":2652,"enrollment":2653,"conditions":2654,"interventions":2655},"NCT00023452","Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection",[58],"2013-09","2001-06",8053,[25],[2637,2656],"Isoniazid (INH) daily for 9 months",{"trials":2658,"activeCount":67},[],{"trials":2660,"activeCount":67},[],{"intervention":2656,"totalTrials":131,"cells":2662},{"EARLY_PHASE1":2663,"PHASE1":2665,"PHASE2":2667,"PHASE3":2669,"PHASE4":2675,"NA":2677},{"trials":2664,"activeCount":67},[],{"trials":2666,"activeCount":67},[],{"trials":2668,"activeCount":67},[],{"trials":2670,"activeCount":67},[2671],{"nctId":2648,"briefTitle":2649,"status":75,"phases":2672,"primaryCompletion":2370,"completion":2651,"start":2652,"enrollment":2653,"conditions":2673,"interventions":2674},[58],[25],[2637,2656],{"trials":2676,"activeCount":67},[],{"trials":2678,"activeCount":67},[],{"intervention":2680,"totalTrials":131,"cells":2681},"gentamicin",{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2686,"PHASE3":2688,"PHASE4":2701,"NA":2703},{"trials":2683,"activeCount":67},[],{"trials":2685,"activeCount":67},[],{"trials":2687,"activeCount":67},[],{"trials":2689,"activeCount":67},[2690],{"nctId":2691,"briefTitle":2692,"status":75,"phases":2693,"completion":2694,"start":2695,"enrollment":2696,"conditions":2697,"interventions":2699},"NCT00128466","Treatment and Diagnosis of Plague",[57,58],"2007-02","2004-08",114,[2698],"Plague",[2680,2700],"streptomycin",{"trials":2702,"activeCount":67},[],{"trials":2704,"activeCount":67},[],{"intervention":2700,"totalTrials":131,"cells":2706},{"EARLY_PHASE1":2707,"PHASE1":2709,"PHASE2":2711,"PHASE3":2713,"PHASE4":2719,"NA":2721},{"trials":2708,"activeCount":67},[],{"trials":2710,"activeCount":67},[],{"trials":2712,"activeCount":67},[],{"trials":2714,"activeCount":67},[2715],{"nctId":2691,"briefTitle":2692,"status":75,"phases":2716,"completion":2694,"start":2695,"enrollment":2696,"conditions":2717,"interventions":2718},[57,58],[2698],[2680,2700],{"trials":2720,"activeCount":67},[],{"trials":2722,"activeCount":67},[],{"intervention":2724,"totalTrials":131,"cells":2725},"7.5ug H1N1 Influenza vaccine",{"EARLY_PHASE1":2726,"PHASE1":2728,"PHASE2":2730,"PHASE3":2732,"PHASE4":2746,"NA":2748},{"trials":2727,"activeCount":67},[],{"trials":2729,"activeCount":67},[],{"trials":2731,"activeCount":67},[],{"trials":2733,"activeCount":67},[2734],{"nctId":2735,"briefTitle":2736,"status":1744,"phases":2737,"primaryCompletion":1966,"completion":2738,"start":2739,"enrollment":2740,"conditions":2741,"interventions":2743},"NCT01040078","Novel Influenza A\u002FH1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month",[58],"2010-06","2009-12",900,[30,2742],"Swine-origin A\u002FH1N1 Influenza",[2724,2744,2745],"15ug H1N1 vaccine","seasonal influenza vaccine",{"trials":2747,"activeCount":67},[],{"trials":2749,"activeCount":67},[],{"intervention":2744,"totalTrials":131,"cells":2751},{"EARLY_PHASE1":2752,"PHASE1":2754,"PHASE2":2756,"PHASE3":2758,"PHASE4":2764,"NA":2766},{"trials":2753,"activeCount":67},[],{"trials":2755,"activeCount":67},[],{"trials":2757,"activeCount":67},[],{"trials":2759,"activeCount":67},[2760],{"nctId":2735,"briefTitle":2736,"status":1744,"phases":2761,"primaryCompletion":1966,"completion":2738,"start":2739,"enrollment":2740,"conditions":2762,"interventions":2763},[58],[30,2742],[2724,2744,2745],{"trials":2765,"activeCount":67},[],{"trials":2767,"activeCount":67},[],{"intervention":2769,"totalTrials":131,"cells":2770},"Tenofovir disoproxil",{"EARLY_PHASE1":2771,"PHASE1":2773,"PHASE2":2775,"PHASE3":2777,"PHASE4":2788,"NA":2790},{"trials":2772,"activeCount":67},[],{"trials":2774,"activeCount":67},[],{"trials":2776,"activeCount":67},[],{"trials":2778,"activeCount":67},[2779],{"nctId":2780,"briefTitle":2781,"status":75,"phases":2782,"primaryCompletion":2783,"completion":2395,"start":2784,"enrollment":2785,"conditions":2786,"interventions":2787},"NCT00119106","Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand",[57,58],"2013-07","2005-06",2413,[16],[2769],{"trials":2789,"activeCount":67},[],{"trials":2791,"activeCount":67},[],{"intervention":2793,"totalTrials":131,"cells":2794},"rVSVΔG-ZEBOV",{"EARLY_PHASE1":2795,"PHASE1":2797,"PHASE2":2799,"PHASE3":2801,"PHASE4":2813,"NA":2815},{"trials":2796,"activeCount":67},[],{"trials":2798,"activeCount":67},[],{"trials":2800,"activeCount":67},[],{"trials":2802,"activeCount":67},[2803],{"nctId":2804,"briefTitle":2805,"status":75,"phases":2806,"primaryCompletion":2807,"completion":2808,"start":652,"enrollment":2809,"conditions":2810,"interventions":2812},"NCT02378753","STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)",[57,58],"2016-11-08","2016-12-05",8651,[2811],"Hemorrhagic Fever, Ebola",[2793],{"trials":2814,"activeCount":67},[],{"trials":2816,"activeCount":67},[],{"intervention":2818,"totalTrials":131,"cells":2819},"JYNNEOS",{"EARLY_PHASE1":2820,"PHASE1":2822,"PHASE2":2824,"PHASE3":2826,"PHASE4":2838,"NA":2840},{"trials":2821,"activeCount":67},[],{"trials":2823,"activeCount":67},[],{"trials":2825,"activeCount":67},[],{"trials":2827,"activeCount":67},[2828],{"nctId":2829,"briefTitle":2830,"status":75,"phases":2831,"primaryCompletion":2832,"completion":2832,"start":2833,"enrollment":2834,"conditions":2835,"interventions":2837},"NCT02977715","JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo",[58],"2025-10-31","2017-02-23",1600,[2836],"Monkeypox Virus Infection",[2818,2818],{"trials":2839,"activeCount":67},[],{"trials":2841,"activeCount":67},[],{"intervention":2843,"totalTrials":131,"cells":2844},"tenofovir disoproxil fumarate",{"EARLY_PHASE1":2845,"PHASE1":2847,"PHASE2":2849,"PHASE3":2859,"PHASE4":2861,"NA":2863},{"trials":2846,"activeCount":67},[],{"trials":2848,"activeCount":67},[],{"trials":2850,"activeCount":67},[2851],{"nctId":2852,"briefTitle":2853,"status":75,"phases":2854,"primaryCompletion":2855,"completion":2855,"start":2604,"enrollment":2856,"conditions":2857,"interventions":2858},"NCT00131677","Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men",[57],"2009-08",400,[2540],[2843],{"trials":2860,"activeCount":67},[],{"trials":2862,"activeCount":67},[],{"trials":2864,"activeCount":67},[],{"intervention":2866,"totalTrials":131,"cells":2867},"Novel monovalent oral poliovirus vaccine type 2",{"EARLY_PHASE1":2868,"PHASE1":2870,"PHASE2":2872,"PHASE3":2884,"PHASE4":2886,"NA":2888},{"trials":2869,"activeCount":67},[],{"trials":2871,"activeCount":67},[],{"trials":2873,"activeCount":67},[2874],{"nctId":2875,"briefTitle":2876,"status":75,"phases":2877,"primaryCompletion":2878,"completion":2878,"start":2879,"enrollment":2880,"conditions":2881,"interventions":2882},"NCT04579510","Immunogenicity nOPV2 With and Without bOPV",[57],"2021-12-23","2021-02-08",795,[27],[2866,2883],"Bivalent oral poliovirus vaccine",{"trials":2885,"activeCount":67},[],{"trials":2887,"activeCount":67},[],{"trials":2889,"activeCount":67},[],{"intervention":2883,"totalTrials":131,"cells":2891},{"EARLY_PHASE1":2892,"PHASE1":2894,"PHASE2":2896,"PHASE3":2902,"PHASE4":2904,"NA":2906},{"trials":2893,"activeCount":67},[],{"trials":2895,"activeCount":67},[],{"trials":2897,"activeCount":67},[2898],{"nctId":2875,"briefTitle":2876,"status":75,"phases":2899,"primaryCompletion":2878,"completion":2878,"start":2879,"enrollment":2880,"conditions":2900,"interventions":2901},[57],[27],[2866,2883],{"trials":2903,"activeCount":67},[],{"trials":2905,"activeCount":67},[],{"trials":2907,"activeCount":67},[],{"intervention":2909,"totalTrials":131,"cells":2910},"Tenofovir\u002Flamivudine\u002Flopinavir-ritonavir",{"EARLY_PHASE1":2911,"PHASE1":2913,"PHASE2":2915,"PHASE3":2929,"PHASE4":2931,"NA":2933},{"trials":2912,"activeCount":67},[],{"trials":2914,"activeCount":67},[],{"trials":2916,"activeCount":67},[2917],{"nctId":2918,"briefTitle":2919,"status":75,"phases":2920,"primaryCompletion":2921,"completion":2922,"start":2923,"enrollment":2924,"conditions":2925,"interventions":2927},"NCT01125696","Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV",[57],"2018-05","2018-08","2012-05",45,[22,2926],"Hepatitis B",[2909,2928],"Zidovudine\u002Flamivudine\u002Flopinavir-ritonavir",{"trials":2930,"activeCount":67},[],{"trials":2932,"activeCount":67},[],{"trials":2934,"activeCount":67},[],{"intervention":2928,"totalTrials":131,"cells":2936},{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2941,"PHASE3":2947,"PHASE4":2949,"NA":2951},{"trials":2938,"activeCount":67},[],{"trials":2940,"activeCount":67},[],{"trials":2942,"activeCount":67},[2943],{"nctId":2918,"briefTitle":2919,"status":75,"phases":2944,"primaryCompletion":2921,"completion":2922,"start":2923,"enrollment":2924,"conditions":2945,"interventions":2946},[57],[22,2926],[2909,2928],{"trials":2948,"activeCount":67},[],{"trials":2950,"activeCount":67},[],{"trials":2952,"activeCount":67},[],{"intervention":2954,"totalTrials":131,"cells":2955},"Zidovudine\u002FLamivudine and either Nevirapine or Nelfinavir",{"EARLY_PHASE1":2956,"PHASE1":2958,"PHASE2":2960,"PHASE3":2971,"PHASE4":2973,"NA":2975},{"trials":2957,"activeCount":67},[],{"trials":2959,"activeCount":67},[],{"trials":2961,"activeCount":67},[2962],{"nctId":2963,"briefTitle":2964,"status":75,"phases":2965,"primaryCompletion":2966,"completion":2967,"start":99,"enrollment":2968,"conditions":2969,"interventions":2970},"NCT00146380","A Study of Zidovudine\u002FLamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding",[57],"2009-01","2013-01",520,[16],[2954],{"trials":2972,"activeCount":67},[],{"trials":2974,"activeCount":67},[],{"trials":2976,"activeCount":67},[],{"intervention":2978,"totalTrials":131,"cells":2979},"ciprofloxacin",{"EARLY_PHASE1":2980,"PHASE1":2982,"PHASE2":2984,"PHASE3":2994,"PHASE4":2996,"NA":2998},{"trials":2981,"activeCount":67},[],{"trials":2983,"activeCount":67},[],{"trials":2985,"activeCount":67},[2986],{"nctId":2987,"briefTitle":2988,"status":75,"phases":2989,"primaryCompletion":343,"completion":343,"start":380,"enrollment":2990,"conditions":2991,"interventions":2992},"NCT01243437","A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans",[57],200,[2698],[2978,2993],"doxyxcycline",{"trials":2995,"activeCount":67},[],{"trials":2997,"activeCount":67},[],{"trials":2999,"activeCount":67},[],{"intervention":2993,"totalTrials":131,"cells":3001},{"EARLY_PHASE1":3002,"PHASE1":3004,"PHASE2":3006,"PHASE3":3012,"PHASE4":3014,"NA":3016},{"trials":3003,"activeCount":67},[],{"trials":3005,"activeCount":67},[],{"trials":3007,"activeCount":67},[3008],{"nctId":2987,"briefTitle":2988,"status":75,"phases":3009,"primaryCompletion":343,"completion":343,"start":380,"enrollment":2990,"conditions":3010,"interventions":3011},[57],[2698],[2978,2993],{"trials":3013,"activeCount":67},[],{"trials":3015,"activeCount":67},[],{"trials":3017,"activeCount":67},[],{"intervention":402,"totalTrials":131,"cells":3019},{"EARLY_PHASE1":3020,"PHASE1":3022,"PHASE2":3024,"PHASE3":3030,"PHASE4":3032,"NA":3034},{"trials":3021,"activeCount":67},[],{"trials":3023,"activeCount":67},[],{"trials":3025,"activeCount":67},[3026],{"nctId":395,"briefTitle":396,"status":75,"phases":3027,"primaryCompletion":398,"completion":398,"start":399,"enrollment":23,"conditions":3028,"interventions":3029},[57],[16,25],[48,402],{"trials":3031,"activeCount":67},[],{"trials":3033,"activeCount":67},[],{"trials":3035,"activeCount":67},[],{"intervention":3037,"totalTrials":131,"cells":3038},"Pyridoxine",{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3043,"PHASE3":3055,"PHASE4":3057,"NA":3059},{"trials":3040,"activeCount":67},[],{"trials":3042,"activeCount":67},[],{"trials":3044,"activeCount":67},[3045],{"nctId":3046,"briefTitle":3047,"status":2305,"phases":3048,"primaryCompletion":3049,"completion":3049,"start":1502,"enrollment":67,"conditions":3050,"interventions":3052},"NCT01730313","Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda - 2012",[57],"2017-07",[3051],"Nodding Syndrome",[3037,3053,3054],"Sodium Valproate","Phenytoin",{"trials":3056,"activeCount":67},[],{"trials":3058,"activeCount":67},[],{"trials":3060,"activeCount":67},[],{"intervention":3053,"totalTrials":131,"cells":3062},{"EARLY_PHASE1":3063,"PHASE1":3065,"PHASE2":3067,"PHASE3":3073,"PHASE4":3075,"NA":3077},{"trials":3064,"activeCount":67},[],{"trials":3066,"activeCount":67},[],{"trials":3068,"activeCount":67},[3069],{"nctId":3046,"briefTitle":3047,"status":2305,"phases":3070,"primaryCompletion":3049,"completion":3049,"start":1502,"enrollment":67,"conditions":3071,"interventions":3072},[57],[3051],[3037,3053,3054],{"trials":3074,"activeCount":67},[],{"trials":3076,"activeCount":67},[],{"trials":3078,"activeCount":67},[],{"intervention":3054,"totalTrials":131,"cells":3080},{"EARLY_PHASE1":3081,"PHASE1":3083,"PHASE2":3085,"PHASE3":3091,"PHASE4":3093,"NA":3095},{"trials":3082,"activeCount":67},[],{"trials":3084,"activeCount":67},[],{"trials":3086,"activeCount":67},[3087],{"nctId":3046,"briefTitle":3047,"status":2305,"phases":3088,"primaryCompletion":3049,"completion":3049,"start":1502,"enrollment":67,"conditions":3089,"interventions":3090},[57],[3051],[3037,3053,3054],{"trials":3092,"activeCount":67},[],{"trials":3094,"activeCount":67},[],{"trials":3096,"activeCount":67},[],{"intervention":360,"totalTrials":131,"cells":3098},{"EARLY_PHASE1":3099,"PHASE1":3101,"PHASE2":3103,"PHASE3":3109,"PHASE4":3111,"NA":3113},{"trials":3100,"activeCount":67},[],{"trials":3102,"activeCount":67},[],{"trials":3104,"activeCount":67},[3105],{"nctId":352,"briefTitle":353,"status":75,"phases":3106,"completion":355,"start":99,"enrollment":356,"conditions":3107,"interventions":3108},[57],[358],[117,360],{"trials":3110,"activeCount":67},[],{"trials":3112,"activeCount":67},[],{"trials":3114,"activeCount":67},[],{"intervention":3116,"totalTrials":131,"cells":3117},"Linezolid",{"EARLY_PHASE1":3118,"PHASE1":3120,"PHASE2":3122,"PHASE3":3133,"PHASE4":3135,"NA":3137},{"trials":3119,"activeCount":67},[],{"trials":3121,"activeCount":67},[],{"trials":3123,"activeCount":67},[3124],{"nctId":3125,"briefTitle":3126,"status":75,"phases":3127,"primaryCompletion":3128,"completion":3128,"start":2514,"enrollment":327,"conditions":3129,"interventions":3132},"NCT00664313","TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB",[56,57],"2010-09",[3130,3131],"Multi-drug Resistant Tuberculosis","Extensively Drug Resistant Tuberculosis",[3116],{"trials":3134,"activeCount":67},[],{"trials":3136,"activeCount":67},[],{"trials":3138,"activeCount":67},[],{"intervention":3140,"totalTrials":131,"cells":3141},"oral versus vaginal metronidazole",{"EARLY_PHASE1":3142,"PHASE1":3144,"PHASE2":3146,"PHASE3":3161,"PHASE4":3163,"NA":3165},{"trials":3143,"activeCount":67},[],{"trials":3145,"activeCount":67},[],{"trials":3147,"activeCount":67},[3148],{"nctId":3149,"briefTitle":3150,"status":75,"phases":3151,"primaryCompletion":3152,"completion":3152,"start":3153,"enrollment":3154,"conditions":3155,"interventions":3160},"NCT00153517","Maternal Effects of Bacterial Vaginosis (BV) Treatment in Pregnancy",[57],"2004-09","1999-10",126,[3156,3157,3158,3159],"Vaginosis, Bacterial","Premature Birth","Birth Weight","Chorioamnionitis",[3140],{"trials":3162,"activeCount":67},[],{"trials":3164,"activeCount":67},[],{"trials":3166,"activeCount":67},[],{"intervention":3168,"totalTrials":131,"cells":3169},"Ad5-gag",{"EARLY_PHASE1":3170,"PHASE1":3172,"PHASE2":3183,"PHASE3":3185,"PHASE4":3187,"NA":3189},{"trials":3171,"activeCount":67},[],{"trials":3173,"activeCount":67},[3174],{"nctId":3175,"briefTitle":3176,"status":1744,"phases":3177,"primaryCompletion":1349,"completion":3178,"start":3179,"enrollment":327,"conditions":3180,"interventions":3182},"NCT02762045","Clinical Trial of Recombinant Adenovirus Type 5 AIDS Vaccine",[56],"2017-12","2016-04",[3181],"Acquired Immunodeficiency Syndrome",[3168],{"trials":3184,"activeCount":67},[],{"trials":3186,"activeCount":67},[],{"trials":3188,"activeCount":67},[],{"trials":3190,"activeCount":67},[],{"intervention":3192,"totalTrials":131,"cells":3193},"Saline Solution",{"EARLY_PHASE1":3194,"PHASE1":3196,"PHASE2":3208,"PHASE3":3210,"PHASE4":3212,"NA":3214},{"trials":3195,"activeCount":67},[],{"trials":3197,"activeCount":67},[3198],{"nctId":3199,"briefTitle":3200,"status":1744,"phases":3201,"primaryCompletion":1896,"completion":3202,"start":343,"enrollment":3203,"conditions":3204,"interventions":3205},"NCT01881581","Safety and Immunogenicity of Recombinant HIV Vaccines for HIV\u002FAIDS",[56],"2014-08",56,[3181],[3192,3206,3207],"D-GPEi","M-GPE",{"trials":3209,"activeCount":67},[],{"trials":3211,"activeCount":67},[],{"trials":3213,"activeCount":67},[],{"trials":3215,"activeCount":67},[],{"intervention":3206,"totalTrials":131,"cells":3217},{"EARLY_PHASE1":3218,"PHASE1":3220,"PHASE2":3226,"PHASE3":3228,"PHASE4":3230,"NA":3232},{"trials":3219,"activeCount":67},[],{"trials":3221,"activeCount":67},[3222],{"nctId":3199,"briefTitle":3200,"status":1744,"phases":3223,"primaryCompletion":1896,"completion":3202,"start":343,"enrollment":3203,"conditions":3224,"interventions":3225},[56],[3181],[3192,3206,3207],{"trials":3227,"activeCount":67},[],{"trials":3229,"activeCount":67},[],{"trials":3231,"activeCount":67},[],{"trials":3233,"activeCount":67},[],{"intervention":3207,"totalTrials":131,"cells":3235},{"EARLY_PHASE1":3236,"PHASE1":3238,"PHASE2":3244,"PHASE3":3246,"PHASE4":3248,"NA":3250},{"trials":3237,"activeCount":67},[],{"trials":3239,"activeCount":67},[3240],{"nctId":3199,"briefTitle":3200,"status":1744,"phases":3241,"primaryCompletion":1896,"completion":3202,"start":343,"enrollment":3203,"conditions":3242,"interventions":3243},[56],[3181],[3192,3206,3207],{"trials":3245,"activeCount":67},[],{"trials":3247,"activeCount":67},[],{"trials":3249,"activeCount":67},[],{"trials":3251,"activeCount":67},[],{"intervention":3253,"totalTrials":131,"cells":3254},"Tetanus-diphtheria toxoids",{"EARLY_PHASE1":3255,"PHASE1":3257,"PHASE2":3270,"PHASE3":3272,"PHASE4":3274,"NA":3276},{"trials":3256,"activeCount":67},[],{"trials":3258,"activeCount":67},[3259],{"nctId":3260,"briefTitle":3261,"status":75,"phases":3262,"completion":687,"start":3263,"enrollment":3264,"conditions":3265,"interventions":3267},"NCT00164411","Pneumococcal Conjugate Vaccine With Pneumococcal Polysaccharide Vaccine and Tetanus\u002FDiphtheria Vaccine",[56],"2004-01",30,[3266],"Pneumococcal Infections",[3253,3268,3269],"7-valent pneumococcal conjugate vaccine","23-valent polysaccharide vaccine",{"trials":3271,"activeCount":67},[],{"trials":3273,"activeCount":67},[],{"trials":3275,"activeCount":67},[],{"trials":3277,"activeCount":67},[],{"intervention":3268,"totalTrials":131,"cells":3279},{"EARLY_PHASE1":3280,"PHASE1":3282,"PHASE2":3288,"PHASE3":3290,"PHASE4":3292,"NA":3294},{"trials":3281,"activeCount":67},[],{"trials":3283,"activeCount":67},[3284],{"nctId":3260,"briefTitle":3261,"status":75,"phases":3285,"completion":687,"start":3263,"enrollment":3264,"conditions":3286,"interventions":3287},[56],[3266],[3253,3268,3269],{"trials":3289,"activeCount":67},[],{"trials":3291,"activeCount":67},[],{"trials":3293,"activeCount":67},[],{"trials":3295,"activeCount":67},[],{"intervention":3269,"totalTrials":131,"cells":3297},{"EARLY_PHASE1":3298,"PHASE1":3300,"PHASE2":3306,"PHASE3":3308,"PHASE4":3310,"NA":3312},{"trials":3299,"activeCount":67},[],{"trials":3301,"activeCount":67},[3302],{"nctId":3260,"briefTitle":3261,"status":75,"phases":3303,"completion":687,"start":3263,"enrollment":3264,"conditions":3304,"interventions":3305},[56],[3266],[3253,3268,3269],{"trials":3307,"activeCount":67},[],{"trials":3309,"activeCount":67},[],{"trials":3311,"activeCount":67},[],{"trials":3313,"activeCount":67},[],{"intervention":3315,"totalTrials":131,"cells":3316},"UC-781 carbomer gel, 0.1% and 0.25%",{"EARLY_PHASE1":3317,"PHASE1":3319,"PHASE2":3327,"PHASE3":3329,"PHASE4":3331,"NA":3333},{"trials":3318,"activeCount":67},[],{"trials":3320,"activeCount":67},[3321],{"nctId":3322,"briefTitle":3323,"status":2305,"phases":3324,"enrollment":67,"conditions":3325,"interventions":3326},"NCT00385554","Botswana Study of UC-781 Vaginal Microbicide",[56],[16],[3315],{"trials":3328,"activeCount":67},[],{"trials":3330,"activeCount":67},[],{"trials":3332,"activeCount":67},[],{"trials":3334,"activeCount":67},[],{"intervention":3336,"totalTrials":131,"cells":3337},"UC 781",{"EARLY_PHASE1":3338,"PHASE1":3340,"PHASE2":3349,"PHASE3":3351,"PHASE4":3353,"NA":3355},{"trials":3339,"activeCount":67},[],{"trials":3341,"activeCount":67},[3342],{"nctId":3343,"briefTitle":3344,"status":75,"phases":3345,"completion":2515,"start":77,"enrollment":3346,"conditions":3347,"interventions":3348},"NCT00446979","Safety Study of UC-781 Vaginal Microbicide",[56],90,[16],[3336],{"trials":3350,"activeCount":67},[],{"trials":3352,"activeCount":67},[],{"trials":3354,"activeCount":67},[],{"trials":3356,"activeCount":67},[],{"intervention":3358,"totalTrials":131,"cells":3359},"PCV7 + PPV23, 2 months",{"EARLY_PHASE1":3360,"PHASE1":3362,"PHASE2":3373,"PHASE3":3375,"PHASE4":3377,"NA":3379},{"trials":3361,"activeCount":67},[],{"trials":3363,"activeCount":67},[3364],{"nctId":3365,"briefTitle":3366,"status":75,"phases":3367,"primaryCompletion":3368,"completion":3368,"start":1967,"enrollment":3369,"conditions":3370,"interventions":3371},"NCT00153543","Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders",[56],"2003-06",86,[3266],[3358,3372],"PCV7 + PPV23, 6 months",{"trials":3374,"activeCount":67},[],{"trials":3376,"activeCount":67},[],{"trials":3378,"activeCount":67},[],{"trials":3380,"activeCount":67},[],{"intervention":3372,"totalTrials":131,"cells":3382},{"EARLY_PHASE1":3383,"PHASE1":3385,"PHASE2":3391,"PHASE3":3393,"PHASE4":3395,"NA":3397},{"trials":3384,"activeCount":67},[],{"trials":3386,"activeCount":67},[3387],{"nctId":3365,"briefTitle":3366,"status":75,"phases":3388,"primaryCompletion":3368,"completion":3368,"start":1967,"enrollment":3369,"conditions":3389,"interventions":3390},[56],[3266],[3358,3372],{"trials":3392,"activeCount":67},[],{"trials":3394,"activeCount":67},[],{"trials":3396,"activeCount":67},[],{"trials":3398,"activeCount":67},[],{"intervention":3400,"totalTrials":131,"cells":3401},"High dose isoniazid",{"EARLY_PHASE1":3402,"PHASE1":3404,"PHASE2":3417,"PHASE3":3419,"PHASE4":3421,"NA":3423},{"trials":3403,"activeCount":67},[],{"trials":3405,"activeCount":67},[3406],{"nctId":3407,"briefTitle":3408,"status":75,"phases":3409,"primaryCompletion":3410,"completion":3410,"start":3411,"enrollment":3412,"conditions":3413,"interventions":3416},"NCT02236078","Brief Bactericidal Activity of Anti-Tuberculosis Drugs",[56],"2020-09-30","2015-11",18,[25,3414,3415],"Drug-resistant Tuberculosis","Isoniazid Resistant Tuberculosis (Disorder)",[3400],{"trials":3418,"activeCount":67},[],{"trials":3420,"activeCount":67},[],{"trials":3422,"activeCount":67},[],{"trials":3424,"activeCount":67},[],{"intervention":116,"totalTrials":3426,"cells":3427},7,{"EARLY_PHASE1":3428,"PHASE1":3430,"PHASE2":3432,"PHASE3":3448,"PHASE4":3462,"NA":3464},{"trials":3429,"activeCount":67},[],{"trials":3431,"activeCount":67},[],{"trials":3433,"activeCount":67},[3434,3438,3444],{"nctId":340,"briefTitle":341,"status":75,"phases":3435,"primaryCompletion":343,"completion":344,"start":345,"enrollment":346,"conditions":3436,"interventions":3437},[57],[292],[349,350,350,350],{"nctId":3439,"briefTitle":3440,"status":75,"phases":3441,"completion":430,"start":303,"enrollment":304,"conditions":3442,"interventions":3443},"NCT00023426","TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis",[57],[25],[350],{"nctId":269,"briefTitle":270,"status":75,"phases":3445,"primaryCompletion":272,"completion":273,"start":274,"enrollment":275,"conditions":3446,"interventions":3447},[56,57],[188],[116,93],{"trials":3449,"activeCount":67},[3450,3454,3458],{"nctId":2259,"briefTitle":2260,"status":75,"phases":3451,"primaryCompletion":2262,"completion":2263,"start":2264,"enrollment":2265,"conditions":3452,"interventions":3453},[58],[25],[350,2248,2268],{"nctId":108,"briefTitle":109,"status":75,"phases":3455,"primaryCompletion":111,"completion":111,"start":112,"enrollment":113,"conditions":3456,"interventions":3457},[58],[25],[116,63,117,93,118,119],{"nctId":285,"briefTitle":286,"status":75,"phases":3459,"completion":288,"start":289,"enrollment":290,"conditions":3460,"interventions":3461},[58],[292],[116,93],{"trials":3463,"activeCount":67},[],{"trials":3465,"activeCount":67},[3466],{"nctId":322,"briefTitle":323,"status":75,"phases":3467,"completion":325,"start":326,"enrollment":327,"conditions":3468,"interventions":3469},[60],[25],[116,330,93],{"intervention":1901,"totalTrials":3426,"cells":3471},{"EARLY_PHASE1":3472,"PHASE1":3474,"PHASE2":3476,"PHASE3":3478,"PHASE4":3491,"NA":3505},{"trials":3473,"activeCount":67},[],{"trials":3475,"activeCount":67},[],{"trials":3477,"activeCount":67},[],{"trials":3479,"activeCount":67},[3480],{"nctId":3481,"briefTitle":3482,"status":75,"phases":3483,"primaryCompletion":3484,"completion":3484,"start":3485,"enrollment":3486,"conditions":3487,"interventions":3489},"NCT01082705","Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children",[58],"2011-06","2010-04",323,[3488],"P. Falciparum Malaria",[1901,3490],"Dihydroartemisinin-piperaquine",{"trials":3492,"activeCount":67},[3493,3497,3501],{"nctId":722,"briefTitle":723,"status":724,"phases":3494,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":3495,"interventions":3496},[59],[730],[709,732,733],{"nctId":735,"briefTitle":736,"status":724,"phases":3498,"primaryCompletion":726,"completion":726,"start":738,"enrollment":739,"conditions":3499,"interventions":3500},[59],[19],[732,709],{"nctId":1892,"briefTitle":1893,"status":75,"phases":3502,"primaryCompletion":1895,"completion":1895,"start":1896,"enrollment":1897,"conditions":3503,"interventions":3504},[59],[1899],[1901,1879],{"trials":3506,"activeCount":67},[3507,3521,3529],{"nctId":3508,"briefTitle":3509,"status":75,"phases":3510,"start":3511,"enrollment":3512,"conditions":3513,"interventions":3514},"NCT00127998","Antimalarial Drug Resistance in Mali",[60],"2005-07",1011,[19],[3515,572,3516,3517,3518,3519,1901,3520],"chloroquine","amodiaquine","amodiaquine+artesunate","amodiaquine+sulfadoxine-pyrimethamine","sulfadoxine-pyrimethamine+artesunate","mefloquine",{"nctId":3522,"briefTitle":3523,"status":75,"phases":3524,"primaryCompletion":3525,"completion":3525,"start":2561,"enrollment":290,"conditions":3526,"interventions":3528},"NCT01043744","Non-malarial Febrile Illness in Children in Areas of Perennial Malaria Transmission",[60],"2011-12",[19,3527],"Non-malarial Febrile Illness",[732],{"nctId":3530,"briefTitle":3531,"status":75,"phases":3532,"completion":1680,"start":3533,"enrollment":3534,"conditions":3535,"interventions":3537},"NCT00153491","Adherence to Lumefantrine-Artemether",[],"2002-08",300,[3536],"Malaria, Uncomplicated",[1901],{"intervention":733,"totalTrials":3539,"cells":3540},4,{"EARLY_PHASE1":3541,"PHASE1":3543,"PHASE2":3545,"PHASE3":3547,"PHASE4":3549,"NA":3567},{"trials":3542,"activeCount":67},[],{"trials":3544,"activeCount":67},[],{"trials":3546,"activeCount":67},[],{"trials":3548,"activeCount":67},[],{"trials":3550,"activeCount":67},[3551,3555],{"nctId":722,"briefTitle":723,"status":724,"phases":3552,"primaryCompletion":726,"completion":726,"start":727,"enrollment":728,"conditions":3553,"interventions":3554},[59],[730],[709,732,733],{"nctId":3556,"briefTitle":3557,"status":75,"phases":3558,"primaryCompletion":3559,"completion":3559,"start":3560,"enrollment":3561,"conditions":3562,"interventions":3564},"NCT01680406","Ethiopia Antimalarial in Vivo Efficacy Study 2012",[59],"2014-12","2012-10",398,[3563],"Plasmodium Vivax Infection",[3565,3566,733],"Artemether-lumefantrine combination","Primaquine",{"trials":3568,"activeCount":67},[3569,3577],{"nctId":3570,"briefTitle":3571,"status":75,"phases":3572,"primaryCompletion":3559,"completion":3559,"start":3573,"enrollment":3574,"conditions":3575,"interventions":3576},"NCT02043652","Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil",[60],"2014-02",119,[19],[733,3566],{"nctId":3508,"briefTitle":3509,"status":75,"phases":3578,"start":3511,"enrollment":3512,"conditions":3579,"interventions":3580},[60],[19],[3515,572,3516,3517,3518,3519,1901,3520],{"intervention":572,"totalTrials":3539,"cells":3582},{"EARLY_PHASE1":3583,"PHASE1":3585,"PHASE2":3587,"PHASE3":3589,"PHASE4":3591,"NA":3609},{"trials":3584,"activeCount":67},[],{"trials":3586,"activeCount":67},[],{"trials":3588,"activeCount":67},[],{"trials":3590,"activeCount":67},[],{"trials":3592,"activeCount":67},[3593,3601,3605],{"nctId":3594,"briefTitle":3595,"status":75,"phases":3596,"completion":89,"start":3597,"enrollment":3598,"conditions":3599,"interventions":3600},"NCT00144352","In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults",[59],"2002-09",540,[19,22,2607],[572],{"nctId":566,"briefTitle":567,"status":75,"phases":3602,"primaryCompletion":558,"completion":558,"start":559,"enrollment":569,"conditions":3603,"interventions":3604},[59],[562],[572,573,574,564,575],{"nctId":1918,"briefTitle":1919,"status":75,"phases":3606,"primaryCompletion":1921,"completion":1921,"start":1922,"enrollment":1923,"conditions":3607,"interventions":3608},[59],[1925],[1927,1905,1928],{"trials":3610,"activeCount":67},[3611],{"nctId":3508,"briefTitle":3509,"status":75,"phases":3612,"start":3511,"enrollment":3512,"conditions":3613,"interventions":3614},[60],[19],[3515,572,3516,3517,3518,3519,1901,3520],{"intervention":656,"totalTrials":436,"cells":3616},{"EARLY_PHASE1":3617,"PHASE1":3619,"PHASE2":3621,"PHASE3":3623,"PHASE4":3625,"NA":3635},{"trials":3618,"activeCount":67},[],{"trials":3620,"activeCount":67},[],{"trials":3622,"activeCount":67},[],{"trials":3624,"activeCount":67},[],{"trials":3626,"activeCount":67},[3627,3631],{"nctId":803,"briefTitle":804,"status":724,"phases":3628,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":3629,"interventions":3630},[59],[27],[790,811,812,656],{"nctId":648,"briefTitle":649,"status":75,"phases":3632,"primaryCompletion":651,"completion":651,"start":652,"enrollment":653,"conditions":3633,"interventions":3634},[59],[27],[635,635,656],{"trials":3636,"activeCount":67},[3637],{"nctId":3638,"briefTitle":3639,"status":75,"phases":3640,"primaryCompletion":3641,"completion":3049,"start":1619,"enrollment":3642,"conditions":3643,"interventions":3644},"NCT02643446","Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine",[],"2017-03",809,[27],[656,3645],"OPV",{"intervention":3566,"totalTrials":436,"cells":3647},{"EARLY_PHASE1":3648,"PHASE1":3650,"PHASE2":3652,"PHASE3":3654,"PHASE4":3656,"NA":3662},{"trials":3649,"activeCount":67},[],{"trials":3651,"activeCount":67},[],{"trials":3653,"activeCount":67},[],{"trials":3655,"activeCount":67},[],{"trials":3657,"activeCount":67},[3658],{"nctId":3556,"briefTitle":3557,"status":75,"phases":3659,"primaryCompletion":3559,"completion":3559,"start":3560,"enrollment":3561,"conditions":3660,"interventions":3661},[59],[3563],[3565,3566,733],{"trials":3663,"activeCount":67},[3664,3668],{"nctId":3570,"briefTitle":3571,"status":75,"phases":3665,"primaryCompletion":3559,"completion":3559,"start":3573,"enrollment":3574,"conditions":3666,"interventions":3667},[60],[19],[733,3566],{"nctId":3669,"briefTitle":3670,"status":75,"phases":3671,"primaryCompletion":3672,"completion":3672,"start":3673,"enrollment":3674,"conditions":3675,"interventions":3678},"NCT03610399","Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil",[60],"2019-03-12","2018-04-09",257,[3676,3677],"P Vivax","Malaria, Vivax",[3566],{"intervention":3565,"totalTrials":436,"cells":3680},{"EARLY_PHASE1":3681,"PHASE1":3683,"PHASE2":3685,"PHASE3":3687,"PHASE4":3689,"NA":3695},{"trials":3682,"activeCount":67},[],{"trials":3684,"activeCount":67},[],{"trials":3686,"activeCount":67},[],{"trials":3688,"activeCount":67},[],{"trials":3690,"activeCount":67},[3691],{"nctId":3556,"briefTitle":3557,"status":75,"phases":3692,"primaryCompletion":3559,"completion":3559,"start":3560,"enrollment":3561,"conditions":3693,"interventions":3694},[59],[3563],[3565,3566,733],{"trials":3696,"activeCount":67},[3697,3705],{"nctId":3698,"briefTitle":3699,"status":75,"phases":3700,"primaryCompletion":3701,"completion":1349,"start":651,"enrollment":3702,"conditions":3703,"interventions":3704},"NCT02600767","Artemether-lumefantrine for Treatment of P. Falciparum Malaria in Brazil",[60],"2016-05",79,[19],[3565],{"nctId":3706,"briefTitle":3707,"status":75,"phases":3708,"primaryCompletion":3709,"completion":3709,"start":3710,"enrollment":3711,"conditions":3712,"interventions":3713},"NCT01326754","Efficacy of Artemether-lumefantrine, Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malawi",[60],"2012-06","2011-08",498,[562],[3565,3714,3490],"Artesunate-amodiaquine combination",{"intervention":3716,"totalTrials":489,"cells":3717},"Bismuth subsalicylate",{"EARLY_PHASE1":3718,"PHASE1":3720,"PHASE2":3722,"PHASE3":3724,"PHASE4":3738,"NA":3740},{"trials":3719,"activeCount":67},[],{"trials":3721,"activeCount":67},[],{"trials":3723,"activeCount":67},[],{"trials":3725,"activeCount":67},[3726],{"nctId":3727,"briefTitle":3728,"status":724,"phases":3729,"primaryCompletion":3730,"completion":3731,"start":3732,"enrollment":3733,"conditions":3734,"interventions":3737},"NCT03535272","Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea",[58],"2023-11-01","2026-04-29","2018-05-20",482,[3735,3736],"Diarrhea Travelers","Antibiotic Resistant Infection",[3716],{"trials":3739,"activeCount":67},[],{"trials":3741,"activeCount":67},[3742],{"nctId":3743,"briefTitle":3744,"status":75,"phases":3745,"primaryCompletion":3746,"completion":3746,"start":3747,"enrollment":2856,"conditions":3748,"interventions":3749},"NCT02047162","Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients--Pakistan",[60],"2014-09","2014-05",[36],[3716],{"intervention":3751,"totalTrials":489,"cells":3752},"Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg",{"EARLY_PHASE1":3753,"PHASE1":3755,"PHASE2":3757,"PHASE3":3759,"PHASE4":3769,"NA":3771},{"trials":3754,"activeCount":67},[],{"trials":3756,"activeCount":67},[],{"trials":3758,"activeCount":67},[],{"trials":3760,"activeCount":67},[3761],{"nctId":3762,"briefTitle":3763,"status":75,"phases":3764,"primaryCompletion":3765,"completion":3765,"start":2537,"enrollment":3766,"conditions":3767,"interventions":3768},"NCT00448669","Botswana TDF\u002FFTC Oral HIV Prophylaxis Trial",[57,58],"2011-03",1219,[16],[3751],{"trials":3770,"activeCount":67},[],{"trials":3772,"activeCount":67},[3773],{"nctId":3774,"briefTitle":3775,"status":75,"phases":3776,"primaryCompletion":1895,"completion":1895,"start":3560,"enrollment":3777,"conditions":3778,"interventions":3779},"NCT04318210","Open Label Extension (OLE) of the TDF2 Study, Botswana",[60],229,[16],[3751],{"intervention":3781,"totalTrials":489,"cells":3782},"folic acid",{"EARLY_PHASE1":3783,"PHASE1":3785,"PHASE2":3787,"PHASE3":3789,"PHASE4":3791,"NA":3793},{"trials":3784,"activeCount":67},[],{"trials":3786,"activeCount":67},[],{"trials":3788,"activeCount":67},[],{"trials":3790,"activeCount":67},[],{"trials":3792,"activeCount":67},[],{"trials":3794,"activeCount":67},[3795,3803],{"nctId":3796,"briefTitle":3797,"status":75,"phases":3798,"enrollment":3799,"conditions":3800,"interventions":3802},"NCT00207558","Blood Folate and Homocysteine Levels Following Administration of Folic Acid According to Different Daily Dosing Schedules:a Simulation of Food Fortification",[60],1100,[3801],"Neural Tube Defects - Spina Bifida and Anencephaly",[3781],{"nctId":3804,"briefTitle":3805,"status":75,"phases":3806,"completion":2784,"start":687,"enrollment":3807,"conditions":3808,"interventions":3810},"NCT00207532","Dosage Effects of Folic Acid on Blood Folates of Honduran Women",[60],100,[3809],"Spina Bifida and Anencephaly",[3781],{"intervention":3490,"totalTrials":489,"cells":3812},{"EARLY_PHASE1":3813,"PHASE1":3815,"PHASE2":3817,"PHASE3":3819,"PHASE4":3825,"NA":3827},{"trials":3814,"activeCount":67},[],{"trials":3816,"activeCount":67},[],{"trials":3818,"activeCount":67},[],{"trials":3820,"activeCount":67},[3821],{"nctId":3481,"briefTitle":3482,"status":75,"phases":3822,"primaryCompletion":3484,"completion":3484,"start":3485,"enrollment":3486,"conditions":3823,"interventions":3824},[58],[3488],[1901,3490],{"trials":3826,"activeCount":67},[],{"trials":3828,"activeCount":67},[3829],{"nctId":3706,"briefTitle":3707,"status":75,"phases":3830,"primaryCompletion":3709,"completion":3709,"start":3710,"enrollment":3711,"conditions":3831,"interventions":3832},[60],[562],[3565,3714,3490],{"intervention":3834,"totalTrials":489,"cells":3835},"hepatitis B vaccine",{"EARLY_PHASE1":3836,"PHASE1":3838,"PHASE2":3840,"PHASE3":3842,"PHASE4":3844,"NA":3855},{"trials":3837,"activeCount":67},[],{"trials":3839,"activeCount":67},[],{"trials":3841,"activeCount":67},[],{"trials":3843,"activeCount":67},[],{"trials":3845,"activeCount":67},[3846],{"nctId":3847,"briefTitle":3848,"status":75,"phases":3849,"completion":3850,"start":699,"enrollment":3851,"conditions":3852,"interventions":3854},"NCT00144313","VaxTeen Hepatitis B Vaccine Booster Study",[59],"2006-01",60,[3853],"Hepatitis",[3834],{"trials":3856,"activeCount":67},[3857],{"nctId":3858,"briefTitle":3859,"status":75,"phases":3860,"primaryCompletion":687,"completion":2419,"start":325,"enrollment":2856,"conditions":3861,"interventions":3862},"NCT00141999","Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents",[],[3853],[3834],{"intervention":3864,"totalTrials":489,"cells":3865},"hepatitis A vaccine",{"EARLY_PHASE1":3866,"PHASE1":3868,"PHASE2":3870,"PHASE3":3872,"PHASE4":3874,"NA":3885},{"trials":3867,"activeCount":67},[],{"trials":3869,"activeCount":67},[],{"trials":3871,"activeCount":67},[],{"trials":3873,"activeCount":67},[],{"trials":3875,"activeCount":67},[3876],{"nctId":3877,"briefTitle":3878,"status":75,"phases":3879,"primaryCompletion":2652,"completion":2652,"start":3880,"enrollment":3881,"conditions":3882,"interventions":3884},"NCT00139113","Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children",[59],"1996-09",248,[3883],"Hepatitis A",[3864],{"trials":3886,"activeCount":67},[3887],{"nctId":3888,"briefTitle":3889,"status":75,"phases":3890,"completion":3891,"start":3892,"enrollment":3893,"conditions":3894,"interventions":3895},"NCT00139139","A Study to Compare the Efficacy of Hepatitis A Vaccine and Immune Globulin When Given After Exposure to Hepatitis A",[60],"2005-05","2003-09",1500,[3883],[3896],"Hepatitis A vaccine",{"intervention":3898,"totalTrials":489,"cells":3899},"chlorproguanil-dapsone",{"EARLY_PHASE1":3900,"PHASE1":3902,"PHASE2":3911,"PHASE3":3913,"PHASE4":3915,"NA":3917},{"trials":3901,"activeCount":67},[],{"trials":3903,"activeCount":67},[3904],{"nctId":3905,"briefTitle":3906,"status":724,"phases":3907,"start":3511,"enrollment":3908,"conditions":3909,"interventions":3910},"NCT00126971","Chlorproguanil-Dapsone in Pregnant Women",[56],132,[19],[3898],{"trials":3912,"activeCount":67},[],{"trials":3914,"activeCount":67},[],{"trials":3916,"activeCount":67},[],{"trials":3918,"activeCount":67},[3919],{"nctId":3920,"briefTitle":3921,"status":75,"phases":3922,"primaryCompletion":3923,"completion":2419,"start":2562,"enrollment":3924,"conditions":3925,"interventions":3926},"NCT00111163","Intermittent Preventive Treatment With Antimalarials in Kenyan Infants",[60],"2006-03",1516,[19,2221],[3927,3928,3898],"sulfadoxine-pyrimethamine with artesunate","amodiaquine with artesunate",{"intervention":2745,"totalTrials":489,"cells":3930},{"EARLY_PHASE1":3931,"PHASE1":3933,"PHASE2":3935,"PHASE3":3937,"PHASE4":3943,"NA":3945},{"trials":3932,"activeCount":67},[],{"trials":3934,"activeCount":67},[],{"trials":3936,"activeCount":67},[],{"trials":3938,"activeCount":67},[3939],{"nctId":2735,"briefTitle":2736,"status":1744,"phases":3940,"primaryCompletion":1966,"completion":2738,"start":2739,"enrollment":2740,"conditions":3941,"interventions":3942},[58],[30,2742],[2724,2744,2745],{"trials":3944,"activeCount":67},[],{"trials":3946,"activeCount":67},[3947],{"nctId":3948,"briefTitle":3949,"status":75,"phases":3950,"primaryCompletion":3951,"completion":2783,"start":3710,"enrollment":3952,"conditions":3953,"interventions":3955},"NCT01906190","Persistence of Immune Response After Vaccination With Influenza Vaccine",[60],"2013-03",207,[2309,3954],"Immunisation Reaction",[2745],{"intervention":330,"totalTrials":131,"cells":3957},{"EARLY_PHASE1":3958,"PHASE1":3960,"PHASE2":3962,"PHASE3":3964,"PHASE4":3966,"NA":3968},{"trials":3959,"activeCount":67},[],{"trials":3961,"activeCount":67},[],{"trials":3963,"activeCount":67},[],{"trials":3965,"activeCount":67},[],{"trials":3967,"activeCount":67},[],{"trials":3969,"activeCount":67},[3970],{"nctId":322,"briefTitle":323,"status":75,"phases":3971,"completion":325,"start":326,"enrollment":327,"conditions":3972,"interventions":3973},[60],[25],[116,330,93],{"intervention":3975,"totalTrials":131,"cells":3976},"mefloquine plus artesunate",{"EARLY_PHASE1":3977,"PHASE1":3979,"PHASE2":3981,"PHASE3":3983,"PHASE4":3985,"NA":3987},{"trials":3978,"activeCount":67},[],{"trials":3980,"activeCount":67},[],{"trials":3982,"activeCount":67},[],{"trials":3984,"activeCount":67},[],{"trials":3986,"activeCount":67},[],{"trials":3988,"activeCount":67},[3989],{"nctId":3990,"briefTitle":3991,"status":75,"phases":3992,"primaryCompletion":2419,"completion":2419,"start":687,"enrollment":3993,"conditions":3994,"interventions":3996},"NCT00164216","Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru",[],208,[3995],"Malaria Falciparum",[3975],{"intervention":3998,"totalTrials":131,"cells":3999},"bivalent oral polio vaccine",{"EARLY_PHASE1":4000,"PHASE1":4002,"PHASE2":4004,"PHASE3":4006,"PHASE4":4008,"NA":4010},{"trials":4001,"activeCount":67},[],{"trials":4003,"activeCount":67},[],{"trials":4005,"activeCount":67},[],{"trials":4007,"activeCount":67},[],{"trials":4009,"activeCount":67},[],{"trials":4011,"activeCount":67},[4012],{"nctId":4013,"briefTitle":4014,"status":75,"phases":4015,"primaryCompletion":4016,"completion":4017,"start":4018,"enrollment":4019,"conditions":4020,"interventions":4022},"NCT01559636","Diarrhea and Bivalent Oral Polio Vaccine Immunity",[60],"2013-08","2013-10","2012-08",699,[4021,36,2311],"Seroimmunity",[3998],{"intervention":4024,"totalTrials":131,"cells":4025},"Vaccination with inactivated polio vaccine",{"EARLY_PHASE1":4026,"PHASE1":4028,"PHASE2":4030,"PHASE3":4032,"PHASE4":4034,"NA":4036},{"trials":4027,"activeCount":67},[],{"trials":4029,"activeCount":67},[],{"trials":4031,"activeCount":67},[],{"trials":4033,"activeCount":67},[],{"trials":4035,"activeCount":67},[],{"trials":4037,"activeCount":67},[4038],{"nctId":4039,"briefTitle":4040,"status":75,"phases":4041,"primaryCompletion":89,"completion":89,"start":99,"enrollment":4042,"conditions":4043,"interventions":4044},"NCT00137696","Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine",[60],473,[27],[4024],{"intervention":4046,"totalTrials":131,"cells":4047},"inactivated influenza A\u002FH5N1 vaccine",{"EARLY_PHASE1":4048,"PHASE1":4050,"PHASE2":4052,"PHASE3":4054,"PHASE4":4056,"NA":4058},{"trials":4049,"activeCount":67},[],{"trials":4051,"activeCount":67},[],{"trials":4053,"activeCount":67},[],{"trials":4055,"activeCount":67},[],{"trials":4057,"activeCount":67},[],{"trials":4059,"activeCount":67},[4060],{"nctId":4061,"briefTitle":4062,"status":2305,"phases":4063,"primaryCompletion":4064,"completion":4064,"start":4065,"enrollment":67,"conditions":4066,"interventions":4067},"NCT00417560","Inactivated Influenza A\u002FH5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses",[60],"2010-08","2007-01",[30],[4046],{"intervention":4069,"totalTrials":131,"cells":4070},"Nuvaring",{"EARLY_PHASE1":4071,"PHASE1":4073,"PHASE2":4075,"PHASE3":4077,"PHASE4":4079,"NA":4081},{"trials":4072,"activeCount":67},[],{"trials":4074,"activeCount":67},[],{"trials":4076,"activeCount":67},[],{"trials":4078,"activeCount":67},[],{"trials":4080,"activeCount":67},[],{"trials":4082,"activeCount":67},[4083],{"nctId":4084,"briefTitle":4085,"status":75,"phases":4086,"primaryCompletion":1619,"completion":1619,"start":2307,"enrollment":2990,"conditions":4087,"interventions":4089},"NCT02529683","Study of Nuvaring Acceptability, Adherence and Biological Effects Among HIV-negative Women in Kenya",[60],[4088],"Hormonal Contraception",[4069],{"intervention":385,"totalTrials":131,"cells":4091},{"EARLY_PHASE1":4092,"PHASE1":4094,"PHASE2":4096,"PHASE3":4098,"PHASE4":4100,"NA":4102},{"trials":4093,"activeCount":67},[],{"trials":4095,"activeCount":67},[],{"trials":4097,"activeCount":67},[],{"trials":4099,"activeCount":67},[],{"trials":4101,"activeCount":67},[],{"trials":4103,"activeCount":67},[4104],{"nctId":376,"briefTitle":377,"status":75,"phases":4105,"primaryCompletion":379,"completion":380,"start":381,"enrollment":382,"conditions":4106,"interventions":4107},[60],[25],[117,118,119,385],{"intervention":4109,"totalTrials":131,"cells":4110},"coformulated TDF\u002FFTC",{"EARLY_PHASE1":4111,"PHASE1":4113,"PHASE2":4115,"PHASE3":4117,"PHASE4":4119,"NA":4121},{"trials":4112,"activeCount":67},[],{"trials":4114,"activeCount":67},[],{"trials":4116,"activeCount":67},[],{"trials":4118,"activeCount":67},[],{"trials":4120,"activeCount":67},[],{"trials":4122,"activeCount":67},[4123],{"nctId":4124,"briefTitle":4125,"status":75,"phases":4126,"primaryCompletion":4127,"completion":4127,"start":2395,"enrollment":4128,"conditions":4129,"interventions":4132},"NCT02074891","Sustainable Healthcenter Implementation PrEP Pilot Study",[],"2018-11",1420,[4130,4131],"HIV Chemoprophylaxis","HIV Preexposure Prophylaxis",[4109],{"intervention":3516,"totalTrials":131,"cells":4134},{"EARLY_PHASE1":4135,"PHASE1":4137,"PHASE2":4139,"PHASE3":4141,"PHASE4":4143,"NA":4145},{"trials":4136,"activeCount":67},[],{"trials":4138,"activeCount":67},[],{"trials":4140,"activeCount":67},[],{"trials":4142,"activeCount":67},[],{"trials":4144,"activeCount":67},[],{"trials":4146,"activeCount":67},[4147],{"nctId":3508,"briefTitle":3509,"status":75,"phases":4148,"start":3511,"enrollment":3512,"conditions":4149,"interventions":4150},[60],[19],[3515,572,3516,3517,3518,3519,1901,3520],{"intervention":3517,"totalTrials":131,"cells":4152},{"EARLY_PHASE1":4153,"PHASE1":4155,"PHASE2":4157,"PHASE3":4159,"PHASE4":4161,"NA":4163},{"trials":4154,"activeCount":67},[],{"trials":4156,"activeCount":67},[],{"trials":4158,"activeCount":67},[],{"trials":4160,"activeCount":67},[],{"trials":4162,"activeCount":67},[],{"trials":4164,"activeCount":67},[4165],{"nctId":3508,"briefTitle":3509,"status":75,"phases":4166,"start":3511,"enrollment":3512,"conditions":4167,"interventions":4168},[60],[19],[3515,572,3516,3517,3518,3519,1901,3520],{"intervention":3518,"totalTrials":131,"cells":4170},{"EARLY_PHASE1":4171,"PHASE1":4173,"PHASE2":4175,"PHASE3":4177,"PHASE4":4179,"NA":4181},{"trials":4172,"activeCount":67},[],{"trials":4174,"activeCount":67},[],{"trials":4176,"activeCount":67},[],{"trials":4178,"activeCount":67},[],{"trials":4180,"activeCount":67},[],{"trials":4182,"activeCount":67},[4183],{"nctId":3508,"briefTitle":3509,"status":75,"phases":4184,"start":3511,"enrollment":3512,"conditions":4185,"interventions":4186},[60],[19],[3515,572,3516,3517,3518,3519,1901,3520],{"intervention":3519,"totalTrials":131,"cells":4188},{"EARLY_PHASE1":4189,"PHASE1":4191,"PHASE2":4193,"PHASE3":4195,"PHASE4":4197,"NA":4199},{"trials":4190,"activeCount":67},[],{"trials":4192,"activeCount":67},[],{"trials":4194,"activeCount":67},[],{"trials":4196,"activeCount":67},[],{"trials":4198,"activeCount":67},[],{"trials":4200,"activeCount":67},[4201],{"nctId":3508,"briefTitle":3509,"status":75,"phases":4202,"start":3511,"enrollment":3512,"conditions":4203,"interventions":4204},[60],[19],[3515,572,3516,3517,3518,3519,1901,3520],{"intervention":3520,"totalTrials":131,"cells":4206},{"EARLY_PHASE1":4207,"PHASE1":4209,"PHASE2":4211,"PHASE3":4213,"PHASE4":4215,"NA":4217},{"trials":4208,"activeCount":67},[],{"trials":4210,"activeCount":67},[],{"trials":4212,"activeCount":67},[],{"trials":4214,"activeCount":67},[],{"trials":4216,"activeCount":67},[],{"trials":4218,"activeCount":67},[4219],{"nctId":3508,"briefTitle":3509,"status":75,"phases":4220,"start":3511,"enrollment":3512,"conditions":4221,"interventions":4222},[60],[19],[3515,572,3516,3517,3518,3519,1901,3520],{"intervention":4224,"totalTrials":131,"cells":4225},"antimicrobial agent in soap",{"EARLY_PHASE1":4226,"PHASE1":4228,"PHASE2":4230,"PHASE3":4232,"PHASE4":4234,"NA":4236},{"trials":4227,"activeCount":67},[],{"trials":4229,"activeCount":67},[],{"trials":4231,"activeCount":67},[],{"trials":4233,"activeCount":67},[],{"trials":4235,"activeCount":67},[],{"trials":4237,"activeCount":67},[4238],{"nctId":4239,"briefTitle":4240,"status":75,"phases":4241,"completion":4242,"start":4243,"enrollment":2990,"conditions":4244,"interventions":4247},"NCT00139100","Evaluation of Antibacterial Soap for Treatment of Lymphedema in a Filariasis-Endemic Area",[60],"2002-03","2001-02",[4245,4246],"Lymphedema","Cellulitis",[4224],{"intervention":4249,"totalTrials":131,"cells":4250},"Rifapentine + isoniazid once weekly for 3 months",{"EARLY_PHASE1":4251,"PHASE1":4253,"PHASE2":4255,"PHASE3":4257,"PHASE4":4259,"NA":4261},{"trials":4252,"activeCount":67},[],{"trials":4254,"activeCount":67},[],{"trials":4256,"activeCount":67},[],{"trials":4258,"activeCount":67},[],{"trials":4260,"activeCount":67},[],{"trials":4262,"activeCount":67},[4263],{"nctId":4264,"briefTitle":4265,"status":75,"phases":4266,"primaryCompletion":4267,"completion":4267,"start":558,"enrollment":4268,"conditions":4269,"interventions":4270},"NCT00164450","TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection",[60],"2008-08",230,[25],[4249],{"intervention":4272,"totalTrials":131,"cells":4273},"Doxycycline treatment",{"EARLY_PHASE1":4274,"PHASE1":4276,"PHASE2":4278,"PHASE3":4280,"PHASE4":4282,"NA":4284},{"trials":4275,"activeCount":67},[],{"trials":4277,"activeCount":67},[],{"trials":4279,"activeCount":67},[],{"trials":4281,"activeCount":67},[],{"trials":4283,"activeCount":67},[],{"trials":4285,"activeCount":67},[4286],{"nctId":4287,"briefTitle":4288,"status":75,"phases":4289,"completion":4290,"start":4291,"conditions":4292,"interventions":4294},"NCT00207584","Randomized Controlled Trial of Doxycycline to Prevent Acquisition of Mycoplasma Pneumoniae in an Outbreak Setting",[60],"1994-04","1994-01",[4293],"Mycoplasma Pneumoniae",[4272],{"intervention":3645,"totalTrials":131,"cells":4296},{"EARLY_PHASE1":4297,"PHASE1":4299,"PHASE2":4301,"PHASE3":4303,"PHASE4":4305,"NA":4307},{"trials":4298,"activeCount":67},[],{"trials":4300,"activeCount":67},[],{"trials":4302,"activeCount":67},[],{"trials":4304,"activeCount":67},[],{"trials":4306,"activeCount":67},[],{"trials":4308,"activeCount":67},[4309],{"nctId":3638,"briefTitle":3639,"status":75,"phases":4310,"primaryCompletion":3641,"completion":3049,"start":1619,"enrollment":3642,"conditions":4311,"interventions":4312},[],[27],[656,3645],{"intervention":4314,"totalTrials":131,"cells":4315},"albendazole vs. combined albendazole\u002Fivermectin treatment",{"EARLY_PHASE1":4316,"PHASE1":4318,"PHASE2":4320,"PHASE3":4322,"PHASE4":4324,"NA":4326},{"trials":4317,"activeCount":67},[],{"trials":4319,"activeCount":67},[],{"trials":4321,"activeCount":67},[],{"trials":4323,"activeCount":67},[],{"trials":4325,"activeCount":67},[],{"trials":4327,"activeCount":67},[4328],{"nctId":4329,"briefTitle":4330,"status":75,"phases":4331,"completion":687,"start":2604,"enrollment":4332,"conditions":4333,"interventions":4339},"NCT00207753","Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections",[60],550,[4334,4335,4336,4337,4338],"Ascariasis","Trichuriasis","Hookworm Infection","Strongyloidiasis","Pediculosis",[4314],{"intervention":4341,"totalTrials":131,"cells":4342},"artemether\u002Flumafantrine vs chloroquine\u002Fsulfadoxine-pyrimethamine",{"EARLY_PHASE1":4343,"PHASE1":4345,"PHASE2":4347,"PHASE3":4349,"PHASE4":4351,"NA":4353},{"trials":4344,"activeCount":67},[],{"trials":4346,"activeCount":67},[],{"trials":4348,"activeCount":67},[],{"trials":4350,"activeCount":67},[],{"trials":4352,"activeCount":67},[],{"trials":4354,"activeCount":67},[4355],{"nctId":4356,"briefTitle":4357,"status":75,"phases":4358,"primaryCompletion":4359,"completion":4359,"start":99,"enrollment":620,"conditions":4360,"interventions":4361},"NCT00229775","Efficacy of Chloroquine + Sulfadoxine Pyrimethamine Versus Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines",[60],"2008-07",[19],[4341],{"intervention":4363,"totalTrials":131,"cells":4364},"PCV7",{"EARLY_PHASE1":4365,"PHASE1":4367,"PHASE2":4369,"PHASE3":4371,"PHASE4":4373,"NA":4375},{"trials":4366,"activeCount":67},[],{"trials":4368,"activeCount":67},[],{"trials":4370,"activeCount":67},[],{"trials":4372,"activeCount":67},[],{"trials":4374,"activeCount":67},[],{"trials":4376,"activeCount":67},[4377],{"nctId":4378,"briefTitle":4379,"status":75,"phases":4380,"primaryCompletion":2307,"completion":3747,"start":3709,"enrollment":4381,"conditions":4382,"interventions":4386},"NCT02133469","PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae",[60],3281,[4383,4384,4385],"Streptococcal Pneumonia","Nasopharyngeal Diseases","Vaccination Adverse Event",[4363,4387],"Hib Vaccine",{"intervention":4387,"totalTrials":131,"cells":4389},{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4394,"PHASE3":4396,"PHASE4":4398,"NA":4400},{"trials":4391,"activeCount":67},[],{"trials":4393,"activeCount":67},[],{"trials":4395,"activeCount":67},[],{"trials":4397,"activeCount":67},[],{"trials":4399,"activeCount":67},[],{"trials":4401,"activeCount":67},[4402],{"nctId":4378,"briefTitle":4379,"status":75,"phases":4403,"primaryCompletion":2307,"completion":3747,"start":3709,"enrollment":4381,"conditions":4404,"interventions":4405},[60],[4383,4384,4385],[4363,4387],{"intervention":3927,"totalTrials":131,"cells":4407},{"EARLY_PHASE1":4408,"PHASE1":4410,"PHASE2":4412,"PHASE3":4414,"PHASE4":4416,"NA":4418},{"trials":4409,"activeCount":67},[],{"trials":4411,"activeCount":67},[],{"trials":4413,"activeCount":67},[],{"trials":4415,"activeCount":67},[],{"trials":4417,"activeCount":67},[],{"trials":4419,"activeCount":67},[4420],{"nctId":3920,"briefTitle":3921,"status":75,"phases":4421,"primaryCompletion":3923,"completion":2419,"start":2562,"enrollment":3924,"conditions":4422,"interventions":4423},[60],[19,2221],[3927,3928,3898],{"intervention":3928,"totalTrials":131,"cells":4425},{"EARLY_PHASE1":4426,"PHASE1":4428,"PHASE2":4430,"PHASE3":4432,"PHASE4":4434,"NA":4436},{"trials":4427,"activeCount":67},[],{"trials":4429,"activeCount":67},[],{"trials":4431,"activeCount":67},[],{"trials":4433,"activeCount":67},[],{"trials":4435,"activeCount":67},[],{"trials":4437,"activeCount":67},[4438],{"nctId":3920,"briefTitle":3921,"status":75,"phases":4439,"primaryCompletion":3923,"completion":2419,"start":2562,"enrollment":3924,"conditions":4440,"interventions":4441},[60],[19,2221],[3927,3928,3898],{"intervention":4443,"totalTrials":131,"cells":4444},"Tranexamic Acid",{"EARLY_PHASE1":4445,"PHASE1":4447,"PHASE2":4449,"PHASE3":4451,"PHASE4":4453,"NA":4455},{"trials":4446,"activeCount":67},[],{"trials":4448,"activeCount":67},[],{"trials":4450,"activeCount":67},[],{"trials":4452,"activeCount":67},[],{"trials":4454,"activeCount":67},[],{"trials":4456,"activeCount":67},[4457],{"nctId":4458,"briefTitle":4459,"status":75,"phases":4460,"completion":4461,"start":4462,"enrollment":3807,"conditions":4463,"interventions":4469},"NCT00111215","Treatment and Management of Women With Bleeding Disorders",[60],"2006-09","2001-01",[4464,4465,4466,4467,4468],"Menorrhagia","Blood Coagulation Disorders","Blood Platelet Disorders","Von Willebrand Disease","Hematologic Disease",[4443,4470],"Desmopressin Acetate",{"intervention":4470,"totalTrials":131,"cells":4472},{"EARLY_PHASE1":4473,"PHASE1":4475,"PHASE2":4477,"PHASE3":4479,"PHASE4":4481,"NA":4483},{"trials":4474,"activeCount":67},[],{"trials":4476,"activeCount":67},[],{"trials":4478,"activeCount":67},[],{"trials":4480,"activeCount":67},[],{"trials":4482,"activeCount":67},[],{"trials":4484,"activeCount":67},[4485],{"nctId":4458,"briefTitle":4459,"status":75,"phases":4486,"completion":4461,"start":4462,"enrollment":3807,"conditions":4487,"interventions":4488},[60],[4464,4465,4466,4467,4468],[4443,4470],{"intervention":4490,"totalTrials":131,"cells":4491},"Raltegravir",{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4498,"PHASE4":4500,"NA":4502},{"trials":4493,"activeCount":67},[],{"trials":4495,"activeCount":67},[],{"trials":4497,"activeCount":67},[],{"trials":4499,"activeCount":67},[],{"trials":4501,"activeCount":67},[],{"trials":4503,"activeCount":67},[4504],{"nctId":4505,"briefTitle":4506,"status":1744,"phases":4507,"primaryCompletion":726,"completion":3709,"start":727,"enrollment":3851,"conditions":4508,"interventions":4509},"NCT01042652","A Trial to Compare Raltegravir Versus Nevirapine as Anchor Drug for HIV+ Chinese IDUs on Methadone Maintenance",[60],[22,16],[4490],{"intervention":3714,"totalTrials":131,"cells":4511},{"EARLY_PHASE1":4512,"PHASE1":4514,"PHASE2":4516,"PHASE3":4518,"PHASE4":4520,"NA":4522},{"trials":4513,"activeCount":67},[],{"trials":4515,"activeCount":67},[],{"trials":4517,"activeCount":67},[],{"trials":4519,"activeCount":67},[],{"trials":4521,"activeCount":67},[],{"trials":4523,"activeCount":67},[4524],{"nctId":3706,"briefTitle":3707,"status":75,"phases":4525,"primaryCompletion":3709,"completion":3709,"start":3710,"enrollment":3711,"conditions":4526,"interventions":4527},[60],[562],[3565,3714,3490],{"intervention":4529,"totalTrials":131,"cells":4530},"Monthly sulfadoxine\u002Fpyrimethamine",{"EARLY_PHASE1":4531,"PHASE1":4533,"PHASE2":4535,"PHASE3":4537,"PHASE4":4539,"NA":4541},{"trials":4532,"activeCount":67},[],{"trials":4534,"activeCount":67},[],{"trials":4536,"activeCount":67},[],{"trials":4538,"activeCount":67},[],{"trials":4540,"activeCount":67},[],{"trials":4542,"activeCount":67},[4543],{"nctId":4544,"briefTitle":4545,"status":75,"phases":4546,"completion":687,"start":4547,"enrollment":4548,"conditions":4549,"interventions":4550},"NCT00126906","Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi",[60],"2002-10",700,[562,16],[4529,4551],"2-dose sulfadoxine\u002Fpyrimethamine",{"intervention":4551,"totalTrials":131,"cells":4553},{"EARLY_PHASE1":4554,"PHASE1":4556,"PHASE2":4558,"PHASE3":4560,"PHASE4":4562,"NA":4564},{"trials":4555,"activeCount":67},[],{"trials":4557,"activeCount":67},[],{"trials":4559,"activeCount":67},[],{"trials":4561,"activeCount":67},[],{"trials":4563,"activeCount":67},[],{"trials":4565,"activeCount":67},[4566],{"nctId":4544,"briefTitle":4545,"status":75,"phases":4567,"completion":687,"start":4547,"enrollment":4548,"conditions":4568,"interventions":4569},[60],[562,16],[4529,4551],{"intervention":4571,"totalTrials":131,"cells":4572},"PCEC rabies vaccine given intradermally",{"EARLY_PHASE1":4573,"PHASE1":4575,"PHASE2":4577,"PHASE3":4579,"PHASE4":4581,"NA":4583},{"trials":4574,"activeCount":67},[],{"trials":4576,"activeCount":67},[],{"trials":4578,"activeCount":67},[],{"trials":4580,"activeCount":67},[],{"trials":4582,"activeCount":67},[],{"trials":4584,"activeCount":67},[4585],{"nctId":4586,"briefTitle":4587,"status":75,"phases":4588,"primaryCompletion":4589,"completion":4016,"start":4590,"enrollment":4591,"conditions":4592,"interventions":4595},"NCT01044199","Study of Intradermal Administration of PCEC Rabies Vaccine",[60],"2009-09","2009-02",130,[4593,4594],"Rabies Prevention","Rabies Exposure",[4571,4596],"PCEC rabies vaccine administered intramuscularly",{"intervention":4596,"totalTrials":131,"cells":4598},{"EARLY_PHASE1":4599,"PHASE1":4601,"PHASE2":4603,"PHASE3":4605,"PHASE4":4607,"NA":4609},{"trials":4600,"activeCount":67},[],{"trials":4602,"activeCount":67},[],{"trials":4604,"activeCount":67},[],{"trials":4606,"activeCount":67},[],{"trials":4608,"activeCount":67},[],{"trials":4610,"activeCount":67},[4611],{"nctId":4586,"briefTitle":4587,"status":75,"phases":4612,"primaryCompletion":4589,"completion":4016,"start":4590,"enrollment":4591,"conditions":4613,"interventions":4614},[60],[4593,4594],[4571,4596],{"intervention":4616,"totalTrials":131,"cells":4617},"Sabin strain inactivated polio vaccine",{"EARLY_PHASE1":4618,"PHASE1":4620,"PHASE2":4622,"PHASE3":4624,"PHASE4":4626,"NA":4628},{"trials":4619,"activeCount":67},[],{"trials":4621,"activeCount":67},[],{"trials":4623,"activeCount":67},[],{"trials":4625,"activeCount":67},[],{"trials":4627,"activeCount":67},[],{"trials":4629,"activeCount":67},[4630],{"nctId":4631,"briefTitle":4632,"status":75,"phases":4633,"primaryCompletion":4634,"completion":4634,"start":4635,"enrollment":4636,"conditions":4637,"interventions":4638},"NCT04614597","A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China",[],"2021-12-21","2020-10-29",774,[27],[4616],{"intervention":4640,"totalTrials":131,"cells":4641},"Chloroquine- P. vivax",{"EARLY_PHASE1":4642,"PHASE1":4644,"PHASE2":4646,"PHASE3":4648,"PHASE4":4650,"NA":4652},{"trials":4643,"activeCount":67},[],{"trials":4645,"activeCount":67},[],{"trials":4647,"activeCount":67},[],{"trials":4649,"activeCount":67},[],{"trials":4651,"activeCount":67},[],{"trials":4653,"activeCount":67},[4654],{"nctId":4655,"briefTitle":4656,"status":75,"phases":4657,"primaryCompletion":2561,"completion":2561,"start":4658,"enrollment":4659,"conditions":4660,"interventions":4661},"NCT01052584","Ethiopia Malaria Therapeutic Efficacy Study",[60],"2009-10",354,[19],[4640,4662,4663],"Artemether-Lumefantrine: P. vivax","Artemether-lumefantrine: P. falciparum",{"intervention":4662,"totalTrials":131,"cells":4665},{"EARLY_PHASE1":4666,"PHASE1":4668,"PHASE2":4670,"PHASE3":4672,"PHASE4":4674,"NA":4676},{"trials":4667,"activeCount":67},[],{"trials":4669,"activeCount":67},[],{"trials":4671,"activeCount":67},[],{"trials":4673,"activeCount":67},[],{"trials":4675,"activeCount":67},[],{"trials":4677,"activeCount":67},[4678],{"nctId":4655,"briefTitle":4656,"status":75,"phases":4679,"primaryCompletion":2561,"completion":2561,"start":4658,"enrollment":4659,"conditions":4680,"interventions":4681},[60],[19],[4640,4662,4663],{"intervention":4663,"totalTrials":131,"cells":4683},{"EARLY_PHASE1":4684,"PHASE1":4686,"PHASE2":4688,"PHASE3":4690,"PHASE4":4692,"NA":4694},{"trials":4685,"activeCount":67},[],{"trials":4687,"activeCount":67},[],{"trials":4689,"activeCount":67},[],{"trials":4691,"activeCount":67},[],{"trials":4693,"activeCount":67},[],{"trials":4695,"activeCount":67},[4696],{"nctId":4655,"briefTitle":4656,"status":75,"phases":4697,"primaryCompletion":2561,"completion":2561,"start":4658,"enrollment":4659,"conditions":4698,"interventions":4699},[60],[19],[4640,4662,4663]]